Methods for delivering drugs to muscles
Conjugating recombinant human lysosomal enzymes with anti-human transferrin receptor antibodies enhances muscle uptake and efficacy, addressing the low efficiency of existing therapies by improving delivery and treatment outcomes for lysosomal diseases.
Patent Information
- Application Number
- JP2023150649
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-02-05
- Filing Date
- 2023-09-19
- Publication Date
- 2024-11-28
- Estimated Expiration
- 2039-02-05
AI Technical Summary
Recombinant human lysosomal enzymes used in enzyme replacement therapy, such as rhGAA, have low uptake efficiency in muscle tissues due to insufficient mannose-6-phosphate (M6P) modification, leading to inadequate drug efficacy and the need for high dosages.
Conjugating recombinant human lysosomal enzymes with anti-human transferrin receptor antibodies, specifically Fab, scFab, scF(ab')2, scFv, or single-chain antibodies, to enhance muscle targeting and uptake.
The conjugation with anti-human transferrin receptor antibodies significantly improves the delivery and efficacy of lysosomal enzymes to muscle tissues, allowing for more effective treatment of muscle dysfunction associated with lysosomal diseases.
Smart Images

Figure 0007591340000002 
Figure 0007591340000003 
Figure 0007591340000004
Abstract
Description
[Technical field]
[0001] The present invention relates to the transport of a drug to muscle, which is to exert its physiological activity in muscle, and more particularly to a conjugate obtained by binding a desired drug to an anti-transferrin antibody, and a method for causing the desired drug to exert its physiological activity in muscle by administering the conjugate. [Background technology]
[0002] In recent years, enzyme replacement therapy for lysosomal diseases caused by functional deficiency of lysosomal enzymes has been established, improving the prognosis and quality of life (QOL) of patients. Pharmaceuticals containing lysosomal enzymes used in enzyme replacement therapy as active ingredients include drugs for glycogen storage disease type 2 (Pompe disease) that use human acid α-glucosidase (hGAA) as the main agent, drugs for mucopolysaccharidosis type 2 (Hunter disease) that use human iduronate-2-sulfatase (hI2S) as the main agent, drugs for Fabry disease that use human α-galactosidase A (hα-GalA) as the main agent, and drugs for Gaucher disease that use human glucocerebrosidase as the main agent, etc.
[0003] Lysosomal enzymes administered to patients in enzyme replacement therapy are taken up into cells to exert their functions. For example, human acid α-glucosidase (hGAA), human iduronate-2-sulfatase (hI2S), and human α-galactosidase A (hα-GalA) are modified with N-glycosylation containing mannose-6-phosphate (M6P) and are taken up into cells via the binding of M6P to the M6P receptor. Human glucocerebrosidase, a treatment for Gaucher disease, is modified with N-glycosylation containing mannose at the reducing end and is taken up into target cells of the reticuloendothelial system such as macrophages via the binding of M6P to the M6P receptor. Regarding the uptake into cells via the binding of M6P to the M6P receptor, bis-phosphate glycans containing two M6Ps have a 100-fold higher affinity for the M6P receptor than mono-phosphate glycans containing one M6P, and the M6P contained in the glycans has a significant effect on the efficiency of uptake of lysosomal enzymes into cells.
[0004] Human lysosomal enzymes used in enzyme replacement therapy are recombinant proteins produced by introducing and expressing genes encoding human lysosomal enzymes into host cells such as CHO cells using gene recombination technology. Recombinant human lysosomal enzymes produced as recombinant proteins must be appropriately glycosylated to exert their medicinal effects. In other words, it is essential for hGAA, hα-GalA, and hI2S to be modified with a glycan containing mannose-6-phosphate, and for human glucocerebrosidase to be modified with a glycan whose reducing end is mannose, in order to exert their medicinal effects.
[0005] In the case of recombinant human acid α-glucosidase (rhGAA), the main target organ where the drug's efficacy should be exerted is muscle, especially skeletal muscle. However, the number of M6P contained in the glycan of rhGAA used in enzyme replacement therapy is an average of one or less per molecule, and therefore most of the glycans are of the mono-phosphate type, and the glycosylation by M6P is insufficient (Non-Patent Document 1). Therefore, the uptake efficiency of rhGAA in the target organs is low, and the dosage per dose is extremely large at 20 mg / kg. Depending on the patient's symptoms, the dosage may be increased to 40 mg / kg, but it is still thought that the function of the administered enzyme is not fully exerted.
[0006] As a method for efficiently taking up rhGAA into target organs, a method using a ligand-receptor system other than M6P-M6P receptor has been developed. For example, it is known that a fusion protein made by fusing hGAA with RAP (receptor-associated protein), a ligand of the low-density lipoprotein receptor family (LDL receptor), is taken up into cells in an M6P-independent manner in experiments using cultured cells (Non-Patent Document 2). According to this method, even rhGAA that is not sufficiently modified with sugar chains containing M6P can be taken up into cells via the binding of RAP and its receptor. [Prior art documents] [Non-patent literature]
[0007] [Non-Patent Document 1] Zhu Y. et al., Biochem J. 389, 619-28 (2005) [Non-Patent Document 2] Prince WS. et al., J Biol. Chem. 279, 35037-46 (2004) Summary of the Invention [Problem to be solved by the invention]
[0008] An object of the present invention is to provide a method and related technology for efficiently taking up into muscle a drug that is to function in muscle when administered to the body. [Means for solving the problem]
[0009] In the research aimed at the above-mentioned object, the present inventors conducted intensive studies and found that recombinant human acid α-glucosidase, which should exert its pharmacological effect in muscles but is not sufficiently transported to muscles as it is, can be efficiently transported to muscles by conjugating it with anti-human transferrin receptor, thereby completing the present invention. That is, the present invention includes the following. 1. A conjugate of an anti-human transferrin receptor antibody and a drug, the drug having a physiological activity that is to exert its function in muscle. 2. The conjugate according to 1 above, wherein the anti-human transferrin receptor antibody is a Fab antibody, an F(ab')2 antibody, or an F(ab') antibody. 3. The conjugate according to 1 above, wherein the anti-human transferrin receptor antibody is a single-chain antibody selected from the group consisting of scFab, scF(ab'), scF(ab')2 and scFv. 4. The conjugate according to 3 above, wherein the single-chain antibody is formed by binding the light chain and heavy chain of the anti-human transferrin receptor antibody via a linker sequence. 5. The conjugate according to 4 above, in which the light chain and heavy chain of the anti-human transferrin receptor antibody are linked via the linker sequence at the C-terminus of the light chain. 6. The conjugate according to 4 above, in which the light chain and heavy chain of the anti-human transferrin receptor antibody are linked via the linker sequence at the C-terminus of the heavy chain. 7. The conjugate according to any one of 4 to 6 above, wherein the linker sequence consists of 8 to 50 amino acid residues. 8. The conjugate described in 7 above, wherein the linker sequence comprises an amino acid sequence selected from the group consisting of the amino acid sequence (Gly Ser), the amino acid sequence (Gly Gly Ser), the amino acid sequence (Gly Gly Gly), SEQ ID NO: 3, and SEQ ID NO: 4. 9. The conjugate according to claim 8, wherein the linker sequence consists of 15 amino acid residues of the amino acid sequence shown in SEQ ID NO:4 repeated three times in succession. 10. A conjugate described in any one of 1 to 9 above, wherein the anti-human transferrin receptor antibody contains the amino acid sequence shown in SEQ ID NO: 22 in the variable region of the light chain and contains the amino acid sequence shown in SEQ ID NO: 23 in the variable region of the heavy chain. 11. The conjugate described in 10 above, wherein the amino acid sequence of the variable region of the light chain has 80% or more homology with the amino acid sequence shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the heavy chain has 80% or more homology with the amino acid sequence shown in SEQ ID NO: 23. 12. The conjugate described in 10 above, wherein the amino acid sequence of the variable region of the light chain has 90% or more homology with the amino acid sequence shown in SEQ ID NO: 22, and the amino acid sequence of the variable region of the heavy chain has 90% or more homology with the amino acid sequence shown in SEQ ID NO: 23. 13. The conjugate according to 10 above, wherein the amino acid sequence of the variable region of the light chain is one in which 1 to 10 amino acids constituting the amino acid sequence shown in SEQ ID NO: 22 are substituted with other amino acids. 14. The conjugate according to 10 above, wherein the amino acid sequence of the variable region of the light chain is one in which 1 to 3 amino acids constituting the amino acid sequence shown in SEQ ID NO: 22 are replaced with other amino acids. 15. The conjugate according to 10 above, wherein the amino acid sequence of the variable region of the heavy chain is one in which 1 to 10 amino acids constituting the amino acid sequence shown in SEQ ID NO: 23 are substituted with other amino acids. 16. The conjugate according to claim 10, wherein the amino acid sequence of the variable region of the heavy chain is such that 1 to 3 amino acids constituting the amino acid sequence shown in SEQ ID NO: 23 are replaced with other amino acids. 17. The conjugate according to claim 10, wherein the amino acid sequence of the variable region of the light chain is such that 1 to 10 amino acids constituting the amino acid sequence shown in SEQ ID NO: 22 are replaced with other amino acids, and the amino acid sequence of the variable region of the heavy chain is such that 1 to 10 amino acids constituting the amino acid sequence shown in SEQ ID NO: 23 are replaced with other amino acids. 18. The conjugate described in 10 above, wherein the amino acid sequence of the variable region of the light chain is such that 1 to 3 amino acids constituting the amino acid sequence shown in SEQ ID NO: 22 are replaced by other amino acids, and the amino acid sequence of the variable region of the heavy chain is such that 1 to 3 amino acids constituting the amino acid sequence shown in SEQ ID NO: 23 are replaced by other amino acids. 19. The conjugate described in claim 10, wherein the anti-human transferrin receptor antibody comprises the amino acid sequence shown in SEQ ID NO: 24 in its light chain and the amino acid sequence shown in SEQ ID NO: 25 in its heavy chain. 20. The conjugate described in 19 above, wherein the amino acid sequence of the light chain has 80% or more homology with the amino acid sequence shown in SEQ ID NO: 24, and the amino acid sequence of the heavy chain has 80% or more homology with the amino acid sequence shown in SEQ ID NO: 25. 21. The conjugate described in 19 above, wherein the amino acid sequence of the light chain has 90% or more homology with the amino acid sequence shown in SEQ ID NO: 24, and the amino acid sequence of the heavy chain has 90% or more homology with the amino acid sequence shown in SEQ ID NO: 25. 22. The conjugate according to any one of 1 to 21 above, wherein the drug is a peptide or a protein. 23. The conjugate according to claim 22, which is selected from the group consisting of the following (1) to (4): (1) the protein is bound to the C-terminus of the light chain of the anti-human transferrin receptor antibody via a peptide bond; (2) The protein is bound to the N-terminus of the light chain of the anti-human transferrin receptor antibody via a peptide bond. (3) The protein is bound to the C-terminus of the heavy chain of the anti-human transferrin receptor antibody via a peptide bond; and (4) The protein is bound to the N-terminus of the heavy chain of the anti-human transferrin receptor antibody via a peptide bond. 24. The conjugate according to claim 23, wherein the protein is bound to the anti-human transferrin receptor antibody via a linker sequence. 25. The conjugate according to claim 24, wherein the linker sequence consists of 1 to 50 amino acid residues. 26. The conjugate described in 25 above, wherein the linker sequence comprises an amino acid sequence selected from the group consisting of one glycine, one serine, the amino acid sequence (Gly Ser), the amino acid sequence (Gly Gly Ser), the amino acid sequence of SEQ ID NO: 3, the amino acid sequence of SEQ ID NO: 4, and amino acid sequences consisting of 1 to 10 consecutive amino acid sequences. 27. A conjugate according to any one of 1 to 28 above, wherein the anti-human transferrin receptor antibody is a humanized anti-human transferrin receptor antibody. 28. The conjugate according to any one of the above 22 to 27, wherein the protein is a lysosomal enzyme. 29. The conjugate according to claim 28, wherein the lysosomal enzyme is human α-galactosidase A. 30. The conjugate according to claim 29, wherein the light chain of the humanized anti-hTfR antibody comprises the amino acid sequence of SEQ ID NO: 24, and the heavy chain of the humanized anti-hTfR antibody is linked to the human α-galactosidase A at its C-terminus via a linker sequence (Gly Ser), and comprises the amino acid sequence shown as SEQ ID NO: 29 as a whole. 31. The conjugate according to claim 28, wherein the lysosomal enzyme is human acid alpha-glucosidase. 32. The conjugate described in 31 above, wherein the light chain of the humanized anti-hTfR antibody comprises the amino acid sequence of SEQ ID NO: 24, and the heavy chain of the humanized anti-hTfR antibody is linked to the human acid α-glucosidase at its C-terminus via a linker sequence (Gly Ser), and comprises the amino acid sequence shown in SEQ ID NO: 27 as a whole. 33. A pharmaceutical composition for improving muscle function, comprising the conjugate according to any one of 1 to 32 above. 34. A pharmaceutical composition for improving muscle dysfunction associated with lysosomal disease, comprising the conjugate described in 28 above. 35. A pharmaceutical composition for improving muscle dysfunction associated with Fabry disease, comprising the conjugate described in 29 or 30 above. 36. A pharmaceutical composition for improving muscle dysfunction associated with Pompe disease, comprising the conjugate according to 31 or 32 above. 37. The pharmaceutical composition according to any one of 33 to 36 above, wherein the muscle is any one of skeletal muscle, cardiac muscle, or smooth muscle. 38. Use of the conjugate according to any one of 28 to 32 above for the manufacture of a pharmaceutical composition for ameliorating muscle dysfunction associated with a lysosomal disease. 39. Use of the conjugate according to 29 or 30 above for the manufacture of a pharmaceutical composition for improving muscle dysfunction associated with Fabry disease. 40. Use of the conjugate according to 31 or 32 above for the manufacture of a pharmaceutical composition for improving muscle dysfunction associated with Pompe disease. 41. Use of the conjugate according to any one of 1 to 32 above as a pharmaceutical composition for improving muscle function. 42. A method for delivering a drug to muscle, comprising preparing the drug as a conjugate coupled to an anti-human transferrin receptor antibody, and administering the conjugate to an individual. 43. The method according to claim 42, wherein the conjugate is a conjugate according to any one of 1 to 32 above. 44. The method according to claim 42 or 43, further comprising the step of improving muscle function of the individual by administering the conjugate. 45. The method according to any one of 42 to 44 above, wherein the individual has a muscular dysfunction. 46. The method according to any one of 42 to 44 above, wherein the individual has muscle dysfunction associated with a lysosomal disease. 47. The method according to claim 46, wherein the lysosomal disease is Fabry disease or Pompe disease. Effect of the Invention
[0010] According to the present invention, a drug intended to function in muscles, particularly a biologically active peptide or protein, can be conjugated with an anti-human transferrin receptor, and thereby efficiently delivered to muscles when administered to the body. In other words, by conjugating a drug with the human transferrin receptor, it is possible to provide a more effective therapeutic agent for diseases accompanied by muscle dysfunction. [Brief description of the drawings]
[0011] [Figure 1] Figure showing the quantitative results of glycogen in the heart. (1) shows the wild-type control group, (2) shows the KO control group, (3) shows the hGAA administration group, and (4) shows the hGAA-anti-hTfR antibody administration group. The vertical bars indicate SD values. The vertical axis indicates glycogen concentration (mg / g wet tissue weight). [Diagram 2] Figure 1 shows the quantitative results of glycogen contained in the diaphragm. (1) to (4), the vertical bars and vertical axis are the same as in Figure 1. [Diagram 3] Figure 1 shows the quantitative results of glycogen in the soleus muscle. (1)-(4), the vertical bars and vertical axis are the same as in Figure 1. [Figure 4] Figure 1 shows the quantitative results of glycogen in the tibialis anterior muscle. (1)-(4) The vertical bars and vertical axis are the same as those in Figure 1. [Diagram 5] Figure 1 shows the quantitative results of glycogen in the quadriceps muscle. (1)-(4) The vertical bars and vertical axis are the same as in Figure 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] In the present invention, the term "muscle" refers to tissue that is mainly composed of skeletal muscle, cardiac muscle, or smooth muscle, and particularly refers to tissue that is mainly composed of skeletal muscle or cardiac muscle. Furthermore, the term "muscle tissue" is understood to be synonymous with muscle.
[0013] In the present invention, a drug that is to exert a physiological activity in muscle is a drug that is not efficiently transported to muscle when administered directly into the blood, and therefore cannot fully exert its physiological activity in muscle. Such a drug may be a low molecular weight compound, a peptide, or a protein. Here, a peptide is one that can exert a physiological activity in muscle (biologically active peptide), but is not efficiently transported to muscle when administered to a living body by itself, and is preferably composed of 2 to 100 amino acid residues, for example, 2 to 50 or 5 to 100 amino acid residues. Here, a protein is one that can exert a physiological activity in muscle (biologically active protein), but is not efficiently transported to muscle when administered to a living body by itself, and includes, for example, lysosomal enzymes such as acid α-glucosidase (GAA) and α-galactosidase A (α-GalA). Moreover, such peptides and proteins may have an artificial amino acid sequence, or may have an amino acid sequence encoded by an animal's gene. Here, there is no particular limitation on the animal species of the gene encoding the peptide or protein, but it is preferably a mammal, more preferably a human, monkey, mouse, livestock animal (horse, pig, sheep, etc.), or pet animal (cat, dog, etc.), and even more preferably a human.
[0014] Lysosomal enzymes that should be utilized as medicines to improve muscle dysfunction associated with lysosomal diseases include, in addition to GAA and α-GalA, α-L-iduronidase (IDUA), iduronate 2-sulfatase (IDS), glucocerebrosidase (GBA), β-galactosidase, GM2 activator protein, β-hexosaminidase A, β-hexosaminidase B, N-acetylglucosamine 1-phosphotransferase, α-mannosidase (LAMAN), β-mannosidase, galactosylceramidase (GALC), saposin C, arylsulfatase A (ARSA), α-L-fucosidase (FUCA1), aspartyl These include glucosaminidase, α-N-acetylgalactosaminidase, acid sphingomyelinase (ASM), β-glucuronidase (GUSB), heparan N-sulfatase (SGSH), α-N-acetylglucosaminidase (NAGLU), acetyl-CoA α-glucosaminide N-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase, acid ceramidase (AC), amylo-1,6-glucosidase, sialidase, aspartylglucosaminidase, palmitoyl protein thioesterase-1 (PPT-1), tripeptidyl peptidase-1 (TPP-1), hyaluronidase-1, CLN1, and CLN2. These enzymes can be delivered to muscles more efficiently when administered in vivo by conjugating them with anti-human transferrin receptor antibodies. Therefore, these conjugates can be used as medicines for improving muscle dysfunction associated with lysosomal diseases.
[0015] Iduronate-2-sulfatase (IDS) fused to anti-hTfR antibody is a therapeutic agent for muscle dysfunction in Hunter syndrome, α-galactosidase A is a therapeutic agent for muscle dysfunction in Fabry disease, α-L-iduronidase (IDUA) is a therapeutic agent for muscle dysfunction in Hurler syndrome or Hurler-Scheie syndrome, glucocerebrosidase (GBA) is a therapeutic agent for muscle dysfunction in Gaucher disease, β-galactosidase is a therapeutic agent for muscle dysfunction in GM1-gangliosidosis types 1-3, and GM2 activator protein is a therapeutic agent for muscle dysfunction in GM1-gangliosidosis types 1-3. As a treatment for muscle dysfunction in GM2-gangliosidosis AB variant, β-hexosaminidase A as a treatment for muscle dysfunction in Sandhoff disease and Tisachs disease, β-hexosaminidase B as a treatment for muscle dysfunction in Sandhoff disease, N-acetylglucosamine-1-phosphotransferase as a treatment for muscle dysfunction in I-cell disease, α-mannosidase (LAMAN) as a treatment for muscle dysfunction in α-mannosidosis, and β-mannosidase as a treatment for muscle dysfunction in β-mannosidosis As therapeutic agents, galactosylceramidase (GALC) is a therapeutic agent for muscle dysfunction in Krabbe disease, saposin C is a therapeutic agent for muscle dysfunction in Gaucher-like storage diseases, arylsulfatase A (ARSA) is a therapeutic agent for muscle dysfunction in metachromatic leukodystrophy (metachromatic leukodystrophy), α-L-fucosidase (FUCA1) is a therapeutic agent for muscle dysfunction in fucosidosis, aspartylglucosaminidase is a therapeutic agent for muscle dysfunction in aspartylglucosaminuria, and α-N-acetylgalactosaminidase is a therapeutic agent for muscle dysfunction in aspartylglucosaminuria. acid sphingomyelinase (ASM) as a treatment for muscle dysfunction in Niemann-Pick disease; beta-glucuronidase (GUSB) as a treatment for muscle dysfunction in Sly syndrome; heparan N-sulfatase (SGSH), α-N-acetylglucosaminidase (NAGLU), acetyl-CoA α-glucosaminide N-acetyltransferase, and N-acetylglucosamine-6-sulfate sulfatase as treatments for muscle dysfunction in Sanfilippo syndrome.Acid ceramidase (AC) can be used as a therapeutic agent for muscle dysfunction in Farber disease, amylo-1,6-glucosidase can be used as a therapeutic agent for muscle dysfunction in Coli disease (Forbes-Coli disease), sialidase can be used as a therapeutic agent for muscle dysfunction in sialidase deficiency, palmitoyl protein thioesterase-1 (PPT-1) can be used as a therapeutic agent for muscle dysfunction in neuronal ceroid lipofuscinosis or Santavuori-Haltia disease, tripeptidyl peptidase-1 (TPP-1) can be used as a therapeutic agent for muscle dysfunction in neuronal ceroid lipofuscinosis or Jansky-Bielschowsky disease, hyaluronidase-1 can be used as a therapeutic agent for muscle dysfunction in hyaluronidase deficiency, acid α-glucosidase (GAA) can be used as a therapeutic agent for muscle dysfunction in Pompe disease, and CLN1 and 2 can be used as a therapeutic agent for muscle dysfunction in Batten disease. In particular, the anti-hTfR antibody of the present invention is expected to reach the brain parenchyma of the cerebrum, neuronal cells of the hippocampus, Purkinje cells of the cerebellum, etc. after passing through the blood-brain barrier, and also to reach the neuronal cells of the striatum of the cerebrum and the neuronal cells of the substantia nigra of the midbrain, and therefore, by fusing it with a protein whose medicinal effect should be exerted in these tissues or cells, the medicinal effect of the protein can be enhanced. However, the medicinal uses are not limited to these diseases.
[0016] In the present invention, the term "lysosomal enzyme" or a term indicating an individual lysosomal enzyme particularly means one having a natural amino acid sequence, but is not limited thereto, and as long as it has a lysosomal enzyme, a lysosomal enzyme that has been subjected to a mutation such as substitution, deletion, or addition to the amino acid sequence of a natural lysosomal enzyme is also included. When an amino acid in the amino acid sequence of a lysosomal enzyme is substituted with another amino acid, the number of amino acids to be substituted is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. When an amino acid in the amino acid sequence of a lysosomal enzyme is deleted, the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. In addition, a mutation that combines the substitution and deletion of these amino acids can be added to the lysosomal enzyme. When amino acids are added to a lysosomal enzyme, preferably 1 to 10 amino acids, more preferably 1 to 5 amino acids, even more preferably 1 to 3 amino acids, and even more preferably 1 to 2 amino acids are added to the amino acid sequence or the N-terminus or C-terminus of the lysosomal enzyme. Mutations that combine addition, substitution, and deletion of these amino acids can also be added to the lysosomal enzyme. The amino acid sequence of the mutated lysosomal enzyme has a homology of preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more with the amino acid sequence of the original lysosomal enzyme. The same applies to proteins and peptides other than lysosomal enzymes.
[0017] Here, when a lysosomal enzyme is said to have lysosomal enzyme activity, it means that when bound to an anti-hTfR antibody, it has 3% or more of the activity that the natural lysosomal enzyme originally has. However, the activity is preferably 10% or more, more preferably 20% or more, even more preferably 50% or more, and even more preferably 80% or more of the activity that the natural lysosomal enzyme originally has. The same applies when the lysosomal enzyme bound to the anti-hTfR antibody is a mutated one. The same also applies to proteins and peptides other than lysosomal enzymes.
[0018] In addition, examples of substitutions of amino acids in the amino acid sequence of a peptide or protein (including lysosomal enzymes and antibodies) with other amino acids include substitutions between amino acids classified in the same group, such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Gly, Ala, Leu, Ile, Val), amide amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids with hydroxyl groups (Ser, Thr), branched amino acids (Val, Leu, Ile), amino acids with small side chains (Gly, Ala, Ser, Thr, Met), and amino acids with non-polar side chains (Ala, Val, Leu, Ile, Pro, Phe, Met). Such substitutions with similar amino acids are predicted to not cause changes in the phenotype of the protein (i.e., conservative amino acid substitutions). Examples of conservative amino acid substitutions are well known in the art and have been described in various publications (see, for example, Bowie et al., Science, 247:1306-1310 (1990)).
[0019] In addition, in the present invention, "homology" or "identity" means the ratio (%) of homologous amino acid residues to all amino acid residues in optimal alignment when two amino acid sequences are compared using a homology calculation algorithm. Comparing two amino acid sequences using homology (or identity) represented by such a ratio is well known in the technical field of the present invention and is easily understood by those skilled in the art. In the present invention, as homology calculation algorithms for calculating the homology between the amino acid sequence of an original protein (including an antibody) and the amino acid sequence of a mutated protein, BLAST (Altschul SF. J Mol. Biol. 215. 403-10, (1990)), Pearson and Lipman's similarity search method (Proc. Natl. Acad. Sci. USA. 85. 2444 (1988)), Smith and Waterman's local homology algorithm (Adv. Appl. Math. 2. 482-9 (1981)), etc. are well known. In addition, blastp, one of the BLAST programs provided on the Internet by the National Institutes of Health, is well known as a means for calculating the homology between two amino acid sequences.
[0020] Lysosomal enzymes are described in detail below, taking acid α-glucosidase and α-galactosidase A as examples.
[0021] Acid α-glucosidase (GAA) is a lysosomal enzyme that has the activity of degrading glycogen. Pompe disease (glycogen storage disease type II) is a disease in which a large amount of glycogen accumulates in the lysosomes of cells due to genetic deficiency of most or all of the activity of acid α-glucosidase, and the main symptom is dysfunction of the cardiac and skeletal muscles. Pompe disease is classified into infantile, toddler, and adult types. The infantile type mainly develops in early infancy, and shows cardiovascular symptoms due to concentric cardiac hypertrophy due to glycogen accumulation in the cardiac muscle, muscle weakness and hypotonia due to skeletal muscle invasion, and is characterized by congenital myopathy symptoms. The infantile type is mainly characterized by skeletal muscle symptoms, and from late infancy, delayed motor development and progressive muscle weakness are shown. The main symptom of the adult type is muscle weakness.
[0022] Alpha-galactosidase A (alpha-GalA) is a lysosomal enzyme that hydrolyzes the terminal alpha-galactosyl bonds of glycolipids and glycoproteins. Trihexosylceramide is one of the substrates of alpha-galactosidase A, and is hydrolyzed by the enzyme at its terminal hexose moiety. Fabry disease is a disease caused by genetic deficiency of most or all of the alpha-GalA activity. The clinical features of Fabry disease are renal failure, angiokeratoma, and cardiovascular abnormalities such as ventricular hypertrophy and mitral valve insufficiency. In addition, atypical types of Fabry disease, which mainly affect the heart, are sometimes distinguished as cardiac Fabry disease.
[0023] As a treatment for patients with lysosomal diseases who lack lysosomal enzymes, enzyme replacement therapy is performed in which lysosomal enzymes produced by genetic recombination technology are administered to patients as medicine. For example, enzyme replacement therapy is performed for patients with Pompe disease using Myozyme (registered trademark), a recombinant human acid α-glucosidase produced by genetic recombination technology. In addition, enzyme replacement therapy is performed for patients with Fabry disease using Fabrayzyme or Replagal (registered trademark), a recombinant human α-galactosidase A produced by genetic recombination technology. One of the tissues in which the lysosomal enzymes used as medicines in these enzyme replacement therapies should be effective is muscle. Therefore, by increasing the supply of lysosomal enzymes to muscles, it is possible to further improve muscle dysfunction associated with lysosomal diseases.
[0024] In the present invention, the term "human acid α-glucosidase" or "hGAA" particularly means hGAA having the same amino acid sequence as natural hGAA, as shown in SEQ ID NO: 1, but is not limited thereto, and includes hGAA having mutations such as substitution, deletion, and addition in the amino acid sequence of natural hGAA, as long as it has hGAA activity. When amino acids in the amino acid sequence of hGAA are replaced with other amino acids, the number of amino acids to be replaced is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. When amino acids in the amino acid sequence of hGAA are deleted, the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. Mutations combining these amino acid substitutions and deletions can also be added to hGAA. When amino acids are added to hGAA, preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2 amino acids are added to the amino acid sequence or the N-terminus or C-terminus of hGAA. Mutations that combine the addition, substitution, and deletion of these amino acids can also be added to hGAA. The amino acid sequence of mutated hGAA preferably has a homology of 80% or more, more preferably a homology of 90% or more, and even more preferably a homology of 95% or more with the amino acid sequence of the original hGAA.
[0025] Here, when hGAA is said to have hGAA activity, it means that when bound to an anti-hTfR antibody, it has 3% or more of the activity inherent to natural hGAA. However, the activity is preferably 10% or more, more preferably 20% or more, even more preferably 50% or more, and even more preferably 80% or more of the activity inherent to natural hGAA. The same applies when the hGAA bound to the anti-hTfR antibody is a mutated one.
[0026] In the present invention, the term "human α-galactosidase A" or "hα-GalA" particularly means hα-GalA having the same amino acid sequence as natural hα-GalA, as shown in SEQ ID NO: 2, but is not limited thereto, and includes those having mutations such as substitution, deletion, and addition in the amino acid sequence of natural hα-GalA, so long as they have hα-GalA activity. When amino acids in the amino acid sequence of hα-GalA are replaced with other amino acids, the number of amino acids to be replaced is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. When amino acids in the amino acid sequence of hα-GalA are deleted, the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. Mutations combining these amino acid substitutions and deletions can also be added to hα-GalA. When amino acids are added to hα-GalA, preferably 1 to 10 amino acids, more preferably 1 to 5 amino acids, even more preferably 1 to 3 amino acids, and even more preferably 1 to 2 amino acids are added to the amino acid sequence or the N-terminus or C-terminus of hα-GalA. Mutations that combine the addition, substitution, and deletion of these amino acids can also be added to hα-GalA. The amino acid sequence of mutated hα-GalA has a homology of preferably 80% or more, more preferably 90% or more, and even more preferably 95% or more with the amino acid sequence of the original hα-GalA.
[0027] Here, when hα-GalA is said to have hα-GalA activity, it means that when it is bound to an anti-hTfR antibody, it has 3% or more of the activity that natural hα-GalA inherently has. However, the activity is preferably 10% or more, more preferably 20% or more, even more preferably 50% or more, and even more preferably 80% or more of the activity that natural hα-GalA inherently has. The same applies when the hα-GalA bound to the anti-hTfR antibody is a mutated one.
[0028] In the present invention, the term "antibody" primarily refers to human antibodies, mouse antibodies, humanized antibodies, chimeric antibodies between human antibodies and antibodies of other mammals, and chimeric antibodies between mouse antibodies and antibodies of other mammals, but is not limited to these as long as it has the property of specifically binding to a specific antigen, and there is also no particular restriction on the animal species of the antibody.
[0029] In the present invention, the term "human antibody" refers to an antibody whose entire protein is encoded by a gene derived from a human. The term "human antibody" also includes antibodies encoded by genes in which mutations have been added to the original human gene without changing the original amino acid sequence for the purpose of increasing gene expression efficiency, etc. In addition, the term "human antibody" also includes antibodies in which a part of a human antibody is replaced with a part of another human antibody by combining two or more genes encoding human antibodies. A human antibody has three complementarity determining regions (CDRs: an abbreviation for complementary determining region) in the immunoglobulin light chain and three complementarity determining regions (CDRs) in the immunoglobulin heavy chain. The three CDRs in the immunoglobulin light chain are called CDR1, CDR2, and CDR3, starting from the N-terminus. The three CDRs in the immunoglobulin heavy chain are also called CDR1, CDR2, and CDR3, starting from the N-terminus. Human antibodies also include antibodies whose antigen specificity, affinity, etc. have been modified by replacing the CDR of a certain human antibody with the CDR of another human antibody.
[0030] In the present invention, the term "human antibody" also includes antibodies in which mutations such as substitution, deletion, and addition have been added to the amino acid sequence of the original antibody by modifying the gene of the original human antibody. When an amino acid in the amino acid sequence of the original antibody is replaced with another amino acid, the number of amino acids to be replaced is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3. When an amino acid in the amino acid sequence of the original antibody is deleted, the number of amino acids to be deleted is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3. Furthermore, antibodies in which mutations that combine these amino acid substitutions and deletions have been added are also human antibodies. When amino acids are added, preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3 amino acids are added to the amino acid sequence or the N-terminus or C-terminus of the original antibody. Antibodies in which mutations that combine these amino acid additions, substitutions, and deletions have been added are also human antibodies. The amino acid sequence of the mutated antibody preferably exhibits 80% or more homology with the amino acid sequence of the original antibody, more preferably 90% or more homology, even more preferably 95% or more homology, and even more preferably 98% or more homology. Therefore, in the present invention, the term "human-derived gene" includes not only the original human-derived gene, but also genes obtained by modifying it.
[0031] Moreover, when we say "mouse antibody," we mean an antibody whose entire protein consists of the same amino acid sequence as an antibody encoded by a gene derived from a mouse. Therefore, "mouse antibody" also includes antibodies encoded by genes in which mutations have been added to the original mouse gene without changing the original amino acid sequence for the purpose of increasing gene expression efficiency, etc. In addition, mouse antibodies also include antibodies in which a part of a mouse antibody is replaced with a part of another mouse antibody by combining two or more genes encoding mouse antibodies. Mouse antibodies have three complementarity determining regions (CDRs) in the immunoglobulin light chain and three complementarity determining regions (CDRs) in the immunoglobulin heavy chain. The three CDRs in the immunoglobulin light chain are called CDR1, CDR2, and CDR3, starting from the N-terminus. The three CDRs in the immunoglobulin heavy chain are also called CDR1, CDR2, and CDR3, starting from the N-terminus. For example, antibodies in which the antigen specificity, affinity, etc. of a mouse antibody have been modified by replacing the CDR of a mouse antibody with the CDR of another mouse antibody are also included in the mouse antibody.
[0032] In the present invention, the term "mouse antibody" also includes an antibody in which mutations such as substitution, deletion, and addition have been added to the amino acid sequence of the original antibody by modifying the gene of the original mouse antibody. When an amino acid in the amino acid sequence of the original antibody is replaced with another amino acid, the number of amino acids to be replaced is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3. When an amino acid in the amino acid sequence of the original antibody is deleted, the number of amino acids to be deleted is preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3. In addition, an antibody in which a mutation combining these amino acid substitutions and deletions has been added is also a mouse antibody. When an amino acid is added, preferably 1 to 20, more preferably 1 to 5, and even more preferably 1 to 3 amino acids are added to the amino acid sequence or the N-terminus or C-terminus of the original antibody. An antibody in which a mutation combining these amino acid additions, substitutions, and deletions has been added is also a mouse antibody. The amino acid sequence of the mutated antibody has preferably 80% or more homology with the amino acid sequence of the original antibody, more preferably 90% or more homology, even more preferably 95% or more homology, and even more preferably 98% or more homology. Therefore, in the present invention, the term "mouse-derived gene" includes not only the original mouse-derived gene, but also genes obtained by modifying it.
[0033] In the present invention, the term "humanized antibody" refers to an antibody in which the amino acid sequence of a part of the variable region (e.g., all or part of the CDR in particular) is derived from a mammal other than human, and the other regions are derived from human. For example, a humanized antibody can be an antibody produced by replacing three complementarity determining regions (CDRs) of an immunoglobulin light chain constituting a human antibody and three complementarity determining regions (CDRs) of an immunoglobulin heavy chain with CDRs of another mammal. The species of other mammal from which the CDRs to be grafted to the appropriate positions of a human antibody are derived is not particularly limited as long as it is a mammal other than human, but is preferably a mouse, rat, rabbit, horse, or a non-human primate, and more preferably a mouse or rat, for example a mouse.
[0034] In the present invention, the term "chimeric antibody" refers to an antibody formed by linking fragments of two or more different antibodies derived from two or more different species.
[0035] A chimeric antibody between a human antibody and an antibody of another mammal is an antibody in which a part of a human antibody is replaced by a part of an antibody of a mammal other than a human. The antibody consists of an Fc region, a Fab region, and a hinge region. A specific example of such a chimeric antibody is a chimeric antibody in which the Fc region is derived from a human antibody while the Fab region is derived from an antibody of another mammal. The hinge region is derived from either a human antibody or an antibody of another mammal. Conversely, a chimeric antibody in which the Fc region is derived from another mammal while the Fab region is derived from a human antibody is included. In this case, too, the hinge region may be derived from either a human antibody or an antibody of another mammal.
[0036] Alternatively, an antibody can be said to be composed of a variable region and a constant region. Another specific example of a chimeric antibody is a heavy chain constant region (C H ) and the light chain constant region (C L ) are derived from human antibodies, while the heavy chain variable region (V H ) and the light chain variable region (V L ) derived from antibodies of other mammals, conversely, the heavy chain constant region (C H ) and the light chain constant region (C L ) are derived from antibodies of other mammals, while the heavy chain variable region (V H ) and the light chain variable region (V L ) derived from a human antibody. Here, the other mammalian species is not particularly limited as long as it is a mammal other than a human, but is preferably a mouse, a rat, a rabbit, a horse, or a non-human primate, and more preferably a mouse.
[0037] A chimeric antibody between a mouse antibody and an antibody of another mammal is an antibody in which a part of the mouse antibody is replaced with a part of the antibody of a mammal other than a mouse. Specific examples of such chimeric antibodies include chimeric antibodies in which the Fc region is derived from a mouse antibody and the Fab region is derived from an antibody of another mammal, and conversely, chimeric antibodies in which the Fc region is derived from another mammal and the Fab region is derived from a mouse antibody. Here, the species of the other mammal is not particularly limited as long as it is a mammal other than a mouse, but is preferably a rat, rabbit, horse, or a primate other than a human.
[0038] Chimeric antibodies of human and mouse antibodies are specifically called "human / mouse chimeric antibodies." Examples of human / mouse chimeric antibodies include chimeric antibodies in which the Fc region is derived from a human antibody and the Fab region is derived from a mouse antibody, and conversely, chimeric antibodies in which the Fc region is derived from a mouse antibody and the Fab region is derived from a human antibody. The hinge region is derived from either a human antibody or a mouse antibody. Other specific examples of human / mouse chimeric antibodies include chimeric antibodies in which the constant region of the heavy chain (C H ) and the light chain constant region (C L ) are derived from human antibodies, while the heavy chain variable region (V H ) and the light chain variable region (V L ) derived from mouse antibodies, whereas the heavy chain constant region (C H ) and the light chain constant region (C L ) is derived from a mouse antibody, while the heavy chain variable region (V H ) and the light chain variable region (V L ) derived from a human antibody.
[0039] An antibody originally has a basic structure consisting of four polypeptide chains: two light immunoglobulin chains and two heavy immunoglobulin chains. However, in the present invention, the term "antibody" refers to an antibody that has this basic structure, as well as: (1) Consists of two polypeptide chains, one light immunoglobulin chain and one heavy immunoglobulin chain, or, as described in more detail below, (2) A single-chain antibody, which is composed of an immunoglobulin light chain linked to a linker sequence at its C-terminus and an immunoglobulin heavy chain linked to the C-terminus of the linker sequence, and (3) Single-chain antibodies are also included, which are composed of a linker sequence attached to the C-terminus of an immunoglobulin heavy chain and an immunoglobulin light chain attached to the C-terminus of the linker sequence. (4) Those consisting of a Fab region in which the Fc region has been deleted from the basic structure of an antibody in the original sense, and those consisting of a Fab region and all or part of the hinge region (including Fab, F(ab') and F(ab')2) These are included in the "antibody" of the present invention.
[0040] Here, Fab is a variable region and a C L One light chain containing the constant region (the light chain constant region) and one variable region and C H A molecule in which one heavy chain containing one region (the constant region of the heavy chain) is bound by disulfide bonds between the cysteine residues present in each heavy chain. In Fab, the heavy chain is composed of a variable region and a C H In addition to the region 1 (part 1 of the heavy chain constant region), a portion of the hinge region may also be included, but in this case the hinge region lacks the cysteine residues that are present in the hinge region and that bind the heavy chains of the antibody. In the Fab, the light chain and the heavy chain are bound by the light chain constant region (C L The cysteine residues in the heavy chain constant region (C H Fab is composed of one light chain and one heavy chain because it lacks the cysteine residues that are present in the hinge region and that bind the heavy chains of antibodies. The light chain that constitutes Fab is composed of the variable region and the C L The heavy chain that constitutes Fab contains the variable region and the C H It may consist of one domain, a variable domain, C HIn addition to the variable region, a portion of the hinge region may be included. In this case, however, the hinge region is selected so as not to contain a cysteine residue that bonds between the heavy chains, so that disulfide bonds are not formed between the two heavy chains at the hinge region. In F(ab'), the heavy chain is composed of a variable region and a C H In addition to the first region, the heavy chain includes all or a part of the hinge region including the cysteine residue that links the heavy chains. F(ab')2 refers to a molecule in which two F(ab')s are bonded by disulfide bonds between the cysteine residues present in the hinge regions of each other. In addition, polymers such as dimers and trimers formed by bonding multiple antibodies directly or via a linker are also antibodies. Furthermore, not limited to these, any one that includes a part of an immunoglobulin molecule and has the property of specifically binding to an antigen is included in the "antibody" as used in the present invention. That is, when the immunoglobulin light chain is referred to in the present invention, it includes one that is derived from an immunoglobulin light chain and has all or a part of the amino acid sequence of its variable region. In addition, when the immunoglobulin heavy chain is referred to, it includes one that is derived from an immunoglobulin heavy chain and has all or a part of the amino acid sequence of its variable region. Therefore, as long as it has all or a part of the amino acid sequence of the variable region, for example, one that has a deleted Fc region is also an immunoglobulin heavy chain.
[0041] In addition, Fc or Fc region refers to the C region in an antibody molecule. H 2 region (part 2 of the heavy chain constant region), and C H This refers to a region that contains a fragment consisting of three regions (part 3 of the heavy chain constant region).
[0042] Furthermore, in the present invention, the term "antibody" means (5) Also included are scFab, scF(ab'), and scF(ab')2, which are single-chain antibodies formed by linking the light chain and heavy chain constituting the Fab, F(ab'), or F(ab')2 shown in (4) above via a linker sequence. Here, scFab, scF(ab'), and scF(ab')2 may be formed by linking a linker sequence to the C-terminus of the light chain and further linking a heavy chain to the C-terminus thereof, or may be formed by linking a linker sequence to the C-terminus of the heavy chain and further linking a light chain to the C-terminus thereof. Furthermore, the antibody of the present invention also includes scFv, which is a single-chain antibody formed by linking the variable region of the light chain and the variable region of the heavy chain via a linker sequence. In the case of scFv, it may be composed of a linker sequence attached to the C-terminus of the light chain variable region and a heavy chain variable region further attached to the C-terminus of that, or it may be composed of a linker sequence attached to the C-terminus of the heavy chain variable region and a light chain variable region further attached to the C-terminus of that.
[0043] In the present invention, the term "single-chain antibody" refers to a protein that is capable of specifically binding to a specific antigen, and is composed of an amino acid sequence containing all or part of the variable region of an immunoglobulin light chain, to which a linker sequence is bound at the C-terminus, and further to which an amino acid sequence containing all or part of the variable region of an immunoglobulin heavy chain is bound at the C-terminus. For example, the above (2), (3), and (5) are included in single-chain antibodies. In addition, a protein that is capable of specifically binding to a specific antigen, and is composed of an amino acid sequence containing all or part of the variable region of an immunoglobulin heavy chain, to which a linker sequence is bound at the C-terminus, and further to which an amino acid sequence containing all or part of the variable region of an immunoglobulin light chain is bound at the C-terminus, is also a "single-chain antibody" in the present invention. In a single-chain antibody in which an immunoglobulin light chain is bound to the C-terminus of an immunoglobulin heavy chain via a linker sequence, the immunoglobulin heavy chain usually lacks an Fc region. The variable region of an immunoglobulin light chain has three complementarity determining regions (CDRs) involved in the antigen specificity of the antibody. Similarly, the variable region of an immunoglobulin heavy chain also has three CDRs. These CDRs are the main regions that determine the antigen specificity of an antibody. Therefore, it is preferable that a single-chain antibody contains all three CDRs of an immunoglobulin heavy chain and all three CDRs of an immunoglobulin light chain. However, as long as the antigen-specific affinity of the antibody is maintained, a single-chain antibody can also be obtained by deleting one or more CDRs.
[0044] In a single-chain antibody, the linker sequence disposed between the light and heavy chains of an immunoglobulin is a peptide chain composed of preferably 2 to 50, more preferably 8 to 50, even more preferably 10 to 30, and even more preferably 12 to 18 or 15 to 25, for example, 15 or 25 amino acid residues. There are no limitations on the amino acid sequence of such a linker sequence, so long as the anti-hTfR antibody formed by linking both chains by the linker sequence retains affinity for hTfR, but preferably the linker sequence is composed of only glycine or glycine and serine, and for example, the amino acid sequence Gly-Ser, the amino acid sequence Gly-Gly-Ser, the amino acid sequence Gly-Gly-Gly, the amino acid sequence Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 3), the amino acid sequence Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 4), or a sequence in which these amino acid sequences are repeated 2 to 10 times or 2 to 5 times. For example, when linking the variable region of an immunoglobulin light chain to the C-terminus of an amino acid sequence consisting of the entire variable region of an immunoglobulin heavy chain via a linker sequence, a linker sequence consisting of a total of 15 amino acids corresponding to three consecutive amino acid sequences Gly-Gly-Gly-Gly-Ser (sequence number 3) is preferred.
[0045] In the present invention, the term "human transferrin receptor" or "hTfR" refers to a membrane protein having the amino acid sequence shown in SEQ ID NO: 5. In one embodiment, the anti-hTfR antibody of the present invention specifically binds to the portion from the 89th cysteine residue from the N-terminus to the phenylalanine at the C-terminus in the amino acid sequence shown in SEQ ID NO: 5 (extracellular domain of hTfR), but is not limited thereto. Furthermore, in the present invention, the term "monkey transferrin receptor" or "monkey TfR" refers particularly to a membrane protein having the amino acid sequence shown in SEQ ID NO: 6 derived from cynomolgus monkeys (Macaca fascicularis). In one embodiment, the anti-hTfR antibody of the present invention also binds to the portion from the 89th cysteine residue from the N-terminus to the phenylalanine at the C-terminus in the amino acid sequence shown in SEQ ID NO: 6 (extracellular domain of monkey TfR), but is not limited thereto.
[0046] The general method for producing antibodies against hTfR is to produce recombinant human transferrin receptor (rhTfR) using cells introduced with an expression vector incorporating the hTfR gene, and then immunize animals such as mice with this rhTfR. Antibody-producing cells against hTfR are extracted from the immunized animal, and hybridoma cells capable of producing antibodies can be produced by fusing these with myeloma cells.
[0047] Also, cells producing antibodies against hTfR can be obtained by immunizing immune system cells obtained from animals such as mice with rhTfR by an extracorporeal immunization method. When using an extracorporeal immunization method, the animal species from which the immune system cells are derived is not particularly limited, but is preferably mouse, rat, rabbit, guinea pig, dog, cat, horse, and primates including human, more preferably mouse, rat, and human, and even more preferably mouse and human. For example, splenocytes prepared from mouse spleen can be used as mouse immune system cells. For human immune system cells, cells prepared from human peripheral blood, bone marrow, spleen, etc. can be used. When human immune system cells are immunized by an extracorporeal immunization method, human antibodies against hTfR can be obtained.
[0048] Hybridoma cells capable of producing antibodies can be produced by immunizing immune system cells using an in vitro immunization method and then fusing the cells with myeloma cells. It is also possible to extract mRNA from the immunized cells, synthesize cDNA, and use this cDNA as a template to amplify DNA fragments containing genes encoding the light and heavy chains of immunoglobulins by PCR reaction, and then use these to artificially reconstruct antibody genes.
[0049] The hybridoma cells obtained as is by the above method also include cells that produce antibodies that recognize proteins other than hTfR as antigens. Furthermore, not all hybridoma cells that produce anti-hTfR antibodies necessarily produce anti-hTfR antibodies that have the desired affinity for hTfR.
[0050] Similarly, artificially reconstructed antibody genes include genes encoding antibodies that recognize proteins other than hTfR as antigens. In addition, not all genes encoding anti-hTfR antibodies necessarily have the desired properties, such as encoding anti-hTfR antibodies that exhibit the desired affinity for hTfR.
[0051] Therefore, a step is required to select hybridoma cells that produce antibodies with the desired characteristics (such as high affinity for hTfR) from the hybridoma cells obtained as described above. In addition, in the case of artificially reconstructed antibody genes, a step is required to select genes that code for antibodies with the desired characteristics (such as high affinity for hTfR) from the antibody genes.
[0052] For example, when selecting hybridoma cells that produce antibodies with high affinity to anti-hTfR antibodies, a method is used in which recombinant hTfR is added to a plate and retained thereon, then the culture supernatant of the hybridoma cells is added, and then antibodies that are not bound to the recombinant hTfR are removed from the plate, and the amount of the antibodies retained on the plate is measured. According to this method, the higher the affinity of the antibodies contained in the culture supernatant of the hybridoma cells added to the plate for hTfR, the greater the amount of the antibodies retained on the plate. Therefore, the amount of the antibodies retained on the plate can be measured, and the hybridoma cells corresponding to the plate that retains more antibodies can be selected as cell lines that produce anti-hTfR antibodies with relatively high affinity to hTfR. From the cell line selected in this way, mRNA can be extracted to synthesize cDNA, and the cDNA can be used as a template to amplify a DNA fragment containing a gene encoding an anti-hTfR antibody using the PCR method, thereby isolating a gene encoding a high affinity antibody.
[0053] When selecting a gene encoding an anti-hTfR antibody with high affinity from the above artificially reconstructed antibody genes, the artificially reconstructed antibody gene is first incorporated into an expression vector, and this expression vector is introduced into a host cell. At this time, the cells used as the host cell are not particularly limited, regardless of whether they are prokaryotic or eukaryotic, as long as they can express the antibody gene by introducing an expression vector incorporating the artificially reconstructed antibody gene, but cells derived from mammals such as humans, mice, and Chinese hamsters are preferred, and in particular, CHO cells derived from Chinese hamster ovaries or NS / 0 cells derived from mouse myeloma are preferred. In addition, the expression vector used to incorporate and express a gene encoding an antibody gene can be used without any particular limitation as long as it can express the gene when introduced into a mammalian cell. The gene incorporated into the expression vector is located downstream of a DNA sequence (gene expression control site) that can regulate the frequency of gene transcription in a mammalian cell. Examples of gene expression control sites that can be used in the present invention include promoters derived from cytomegalovirus, SV40 early promoter, human elongation factor-1 alpha (EF-1α) promoter, and human ubiquitin C promoter.
[0054] Mammalian cells into which such an expression vector has been introduced express the antibody encoded by the above-mentioned artificially reconstructed gene incorporated in the expression vector. When selecting cells producing antibodies with high affinity to anti-hTfR antibodies from the cells thus obtained expressing the artificially reconstructed antibodies, a method is used in which recombinant hTfR is added to a plate and retained thereon, the recombinant hTfR is contacted with the cell culture supernatant, and antibodies not bound to the recombinant hTfR are then removed from the plate, and the amount of antibody retained on the plate is measured. According to this method, the higher the affinity of the antibody contained in the cell culture supernatant for hTfR, the greater the amount of antibody retained on the plate. Therefore, by measuring the amount of antibody retained on the plate, cells corresponding to the plate retaining a greater amount of antibody can be selected as a cell line producing anti-hTfR antibodies with relatively high affinity for hTfR, and thus a gene encoding an anti-hTfR antibody with high affinity for hTfR can be selected. From the cell line selected in this manner, a DNA fragment containing the gene encoding the anti-hTfR antibody can be amplified by PCR, allowing the gene encoding the high-affinity antibody to be isolated.
[0055] Selection of a gene encoding an anti-hTfR antibody with high affinity from the above artificially reconstructed antibody genes can also be performed by incorporating the artificially reconstructed antibody gene into an expression vector, introducing this expression vector into E. coli, and selecting E. coli having the desired gene using a culture supernatant obtained by culturing this E. coli or a solution containing an antibody obtained by dissolving E. coli in the same manner as in the above-mentioned selection of hybridoma cells. The selected E. coli strain expresses a gene encoding an anti-hTfR antibody with relatively high affinity for hTfR. A gene encoding an anti-hTfR antibody with relatively high affinity for hTfR can be isolated from this E. coli strain. When the antibody is to be secreted into the culture supernatant of E. coli, the antibody gene may be incorporated into an expression vector so that a secretion signal sequence is bound to the N-terminus.
[0056] Another method for selecting a gene encoding an anti-hTfR antibody with high affinity is to retain and express the antibody encoded by the above-mentioned artificially reconstructed antibody gene on a phage particle. In this case, the antibody gene is reconstructed as a gene encoding a single-chain antibody. The method for retaining an antibody on a phage particle is described in International Publications (WO1997 / 09436, WO1995 / 11317) and is well known. When selecting a phage carrying an antibody with high affinity for an anti-hTfR antibody from phages carrying antibodies encoded by artificially reconstructed antibody genes, a method is used in which recombinant hTfR is added to a plate and retained, then contacted with the phage, and then phages not bound to the recombinant hTfR are removed from the plate, and the amount of phage retained on the plate is measured. According to this method, the higher the affinity of the antibody retained on the phage particle for hTfR, the greater the amount of phage retained on the plate. Therefore, the amount of phages retained on the plate can be measured, and phage particles corresponding to the plate retaining a larger number of phages can be selected as phage particles that produce anti-hTfR antibodies having a relatively high affinity for hTfR, and thus a gene encoding an anti-hTfR antibody having a high affinity for hTfR can be selected. From the phage particles selected in this way, a DNA fragment containing the gene encoding the anti-hTfR antibody can be amplified by PCR, and the gene encoding the high affinity antibody can be isolated.
[0057] cDNA or phage DNA can be prepared from cells such as hybridoma cells that produce an antibody having high affinity to the above-mentioned anti-hTfR antibody, or from phage particles that have an antibody having high affinity to the anti-hTfR antibody, and using this as a template, a DNA fragment containing a gene encoding all or a part of the light chain of the anti-hTfR antibody, the heavy chain of the anti-hTfR antibody, or a single-chain antibody that is an anti-hTfR antibody can be amplified and isolated by the PCR method, etc. Similarly, a DNA fragment containing a gene encoding all or a part of the variable region of the light chain of the anti-hTfR antibody, and a DNA fragment containing a gene encoding all or a part of the variable region of the heavy chain of the anti-hTfR antibody can also be amplified and isolated by the PCR method, etc.
[0058] A high-affinity anti-hTfR antibody can be produced by incorporating all or part of the genes encoding the light and heavy chains of this high-affinity anti-hTfR antibody into an expression vector, transforming host cells such as mammalian cells with this expression vector, and culturing the resulting transformed cells. The amino acid sequence of the anti-hTfR antibody can also be translated from the base sequence of the gene encoding the isolated anti-hTfR antibody, and a DNA fragment encoding this amino acid sequence can be artificially synthesized. When artificially synthesizing a DNA fragment, the expression level of the anti-hTfR antibody in the host cell can be increased by selecting appropriate codons.
[0059] In order to add mutations such as substitutions, deletions, and additions to the amino acid sequence of the original anti-hTfR antibody, appropriate mutations can also be added to the gene encoding the anti-hTfR antibody contained in the isolated DNA fragment. The gene encoding the anti-hTfR antibody after the mutations have preferably 80% or more homology with the original gene, more preferably 90% or more homology, but there is no particular limit to the homology as long as the affinity for hTfR is not lost. By adding mutations to the amino acid sequence, it is possible to modify the number and type of sugar chains that bind to the anti-hTfR antibody, thereby increasing the stability of the anti-hTfR antibody in vivo.
[0060] When a mutation is added to a gene encoding all or a part of the variable region of the light chain of an anti-hTfR antibody, the gene after the mutation has preferably 80% or more homology with the original gene, more preferably 90% or more homology, but there is no particular limit to the homology as long as the affinity for hTfR is not lost. When an amino acid in the amino acid sequence of the variable region of the light chain is replaced with another amino acid, the number of amino acids to be replaced is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. When an amino acid in the amino acid sequence of the variable region of the light chain is deleted, the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. Mutations that combine the replacement and deletion of these amino acids can also be added. When amino acids are added to the light chain variable region, preferably 1 to 10 amino acids, more preferably 1 to 5 amino acids, even more preferably 1 to 3 amino acids, and even more preferably 1 to 2 amino acids are added to the amino acid sequence of the light chain variable region or to the N-terminal side or C-terminal side of the light chain variable region. Mutations combining addition, substitution, and deletion of these amino acids can also be added. The amino acid sequence of the mutated light chain variable region has preferably 80% or more homology with the amino acid sequence of the original light chain variable region, more preferably 90% or more homology, and even more preferably 95% or more homology. In particular, when an amino acid in the amino acid sequence of the CDR is replaced with another amino acid, the number of amino acids to be replaced is preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 to 2. When an amino acid in the amino acid sequence of the CDR is deleted, the number of amino acids to be deleted is preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 to 2. Mutations combining substitution and deletion of these amino acids can also be added. When amino acids are added, preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 to 2 amino acids are added to the amino acid sequence or to the N-terminus or C-terminus. Mutations that combine addition, substitution, and deletion of these amino acids can also be added.The amino acid sequence of each mutated CDR preferably has 80% or more homology with the original amino acid sequence of each CDR, more preferably 90% or more homology, and even more preferably 95% or more homology.
[0061] When a mutation is added to a gene encoding all or a part of the variable region of the heavy chain of an anti-hTfR antibody, the gene after the mutation has preferably 80% or more homology with the original gene, more preferably 90% or more homology, but there is no particular limit to the homology as long as the affinity for hTfR is not lost. When an amino acid in the amino acid sequence of the variable region of the heavy chain is replaced with another amino acid, the number of amino acids to be replaced is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. When an amino acid in the amino acid sequence of the variable region of the heavy chain is deleted, the number of amino acids to be deleted is preferably 1 to 10, more preferably 1 to 5, even more preferably 1 to 3, and even more preferably 1 to 2. Mutations that combine the replacement and deletion of these amino acids can also be added. When amino acids are added to the heavy chain variable region, preferably 1 to 10 amino acids, more preferably 1 to 5 amino acids, even more preferably 1 to 3 amino acids, and even more preferably 1 to 2 amino acids are added to the amino acid sequence of the heavy chain variable region or to the N-terminal side or C-terminal side. Mutations combining addition, substitution, and deletion of these amino acids can also be added. The amino acid sequence of the mutated heavy chain variable region has preferably 80% or more homology with the original amino acid sequence of the heavy chain variable region, more preferably 90% or more homology, and even more preferably 95% or more homology. In particular, when amino acids in the amino acid sequence of the CDR are replaced with other amino acids, the number of amino acids to be replaced is preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 to 2. When amino acids in the amino acid sequence of the CDR are deleted, the number of amino acids to be deleted is preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 to 2. Mutations combining substitution and deletion of these amino acids can also be added. When amino acids are added, preferably 1 to 5, more preferably 1 to 3, and even more preferably 1 to 2 amino acids are added to the amino acid sequence or to the N-terminus or C-terminus. Mutations that combine addition, substitution, and deletion of these amino acids can also be added.The amino acid sequence of each mutated CDR preferably has 80% or more homology with the original amino acid sequence of each CDR, more preferably 90% or more homology, and even more preferably 95% or more homology.
[0062] Mutations in both the light chain and heavy chain variable regions of the anti-hTfR antibody can be added by combining the above-mentioned mutations in the light chain variable region of the anti-hTfR antibody with the above-mentioned mutations in the heavy chain variable region of the anti-hTfR antibody.
[0063] Substitutions of amino acids in the amino acid sequences of the light and heavy chains of the above-mentioned anti-hTfR antibodies with other amino acids include, for example, substitutions between amino acids classified in the same group, such as aromatic amino acids (Phe, Trp, Tyr), aliphatic amino acids (Gly, Ala, Leu, Ile, Val), amide amino acids (Gln, Asn), basic amino acids (Lys, Arg, His), acidic amino acids (Glu, Asp), amino acids with hydroxyl groups (Ser, Thr), branched amino acids (Val, Leu, Ile), amino acids with small side chains (Gly, Ala, Ser, Thr, Met), and amino acids with nonpolar side chains (Ala, Val, Leu, Ile, Pro, Phe, Met). Such substitutions with similar amino acids are predicted to not cause changes in the phenotype of the protein (i.e., conservative amino acid substitutions). Examples of conservative amino acid substitutions are well known in the art and have been described in various publications (see, for example, Bowie et al., Science, 247:1306-1310 (1990)).
[0064] In addition, when an amino acid is added to the C-terminus or N-terminus of an anti-hTfR antibody by mutation, and the anti-hTfR antibody is linked to a drug (including a physiologically active protein) that is to function in muscle via that amino acid, that amino acid is considered to form part of the anti-hTfR antibody in the linkage.
[0065] Anti-hTfR antibodies obtained by culturing cells that produce anti-hTfR antibodies with relatively high affinity to hTfR selected by the above-mentioned methods, and anti-hTfR antibodies obtained by expressing a gene that encodes an anti-hTfR antibody with high affinity, can also be modified to antibodies with desired properties by introducing mutations such as substitutions, deletions, and additions into their amino acid sequences. Introduction of mutations into the amino acid sequence of an anti-hTfR antibody is carried out by making a mutation in the gene corresponding to that amino acid sequence.
[0066] The affinity of an anti-hTfR antibody for hTfR can be adjusted appropriately by adding mutations such as substitutions, deletions, and additions to the amino acid sequence of the variable region of the antibody. For example, if the affinity of an antibody to an antigen is high and the dissociation constant in an aqueous solution is extremely low, the antibody may not dissociate from the antigen when administered to a living body, resulting in functional problems. In such cases, by introducing mutations into the variable region of the antibody, the dissociation constant can be adjusted stepwise to 2 to 5 times, 5 to 10 times, 10 to 100 times, etc., of the original antibody, and the most preferable antibody that meets the purpose can be obtained. Conversely, by introducing the mutations, the dissociation constant can also be adjusted stepwise to 1 / 2 to 1 / 5 times, 1 / 5 to 1 / 10 times, 1 / 10 to 1 / 100 times, etc., of the original antibody.
[0067] Introduction of mutations such as substitutions, deletions, and additions into the amino acid sequence of an anti-hTfR antibody can be carried out, for example, by using a gene encoding an anti-hTfR antibody as a template and introducing mutations into specific sites in the base sequence of the gene by a method such as PCR, or by introducing mutations randomly.
[0068] Mutations can be introduced into the amino acid sequence of an anti-hTfR antibody for the purpose of adjusting the affinity between the antibody and hTfR, for example, by incorporating a gene encoding an anti-hTfR antibody, which is a single-chain antibody, into a phagemid, using this phagemid to produce a phage that expresses a single-chain antibody on the capsid surface, and propagating the phage while introducing mutations into the gene encoding the single-chain antibody by applying a mutagen or the like, and then selecting from the propagated phages a phage that expresses a single-chain antibody with a desired dissociation constant by the method described above, or by purifying using an antigen column under certain conditions.
[0069] The antibody having a relatively high affinity for hTfR obtained by the above-mentioned method for selecting cells producing high affinity antibodies can be a humanized antibody if it is an antibody of an animal other than human. A humanized antibody is an antibody obtained by replacing (transplanting) an appropriate region of a human antibody with the amino acid sequence of a part of the variable region of an antibody of an animal other than human (e.g., all or part of the CDR in particular) while maintaining the specificity for the antigen. For example, an example of a humanized antibody is an antibody in which three complementarity determining regions (CDRs) of an immunoglobulin light chain constituting a human antibody and three complementarity determining regions (CDRs) of an immunoglobulin heavy chain are replaced with CDRs of another mammal. The species from which the CDRs incorporated into a human antibody are derived is not particularly limited as long as it is a mammal other than human, but is preferably a mouse, rat, rabbit, horse, or a non-human primate, more preferably a mouse or rat, and even more preferably a mouse. Here, it is well known that in order to reproduce the original activity of a donor antibody, it may be necessary to replace not only the CDRs of the antibody of a non-human mammal but also the amino acid sequence of the region outside the CDR that is involved in maintaining the CDR structure or binding to an antigen with the corresponding site of the acceptor human antibody. The region outside the CDR is also called the framework region (FR). In other words, the production of a humanized antibody includes the process of transplanting the CDR (and the surrounding FR, if necessary) of an antibody of a non-human mammal in place of the CDR (and the surrounding FR, if necessary) of the variable region of a human antibody.
[0070] As described above, in a humanized antibody, the region of the antibody of a non-human mammal that is grafted onto the variable region of the original human antibody generally includes the CDR itself, or the CDR and its surrounding FR. However, since the FR grafted together with the CDR is also involved in maintaining the structure of the CDR or binding with an antigen, and is considered to have a function of substantially determining the complementarity of the antibody, the term "CDR" in the present invention refers to a region that is grafted or can be grafted from an antibody of a non-human mammal to a humanized antibody when producing a humanized antibody. In other words, even if a region is generally considered to be a FR, it is included in the CDR in the present invention as long as it is involved in maintaining the structure of the CDR or binding with an antigen, and is considered to have a function of substantially determining the complementarity of the antibody.
[0071] The case where the anti-hTfR antibody is a humanized antibody or a human antibody will be described in more detail below. The light chain of a human antibody includes a lambda chain and a kappa chain. The light chain constituting the anti-hTfR antibody may be either a lambda chain or a kappa chain. Human heavy chains include a gamma chain, a μ chain, an alpha chain, a sigma chain, and an epsilon chain, which correspond to IgG, IgM, IgA, IgD, and IgE, respectively. The heavy chain constituting the anti-hTfR antibody may be either a gamma chain, a μ chain, an alpha chain, a sigma chain, and an epsilon chain, but is preferably a gamma chain. Furthermore, the gamma chain of the human heavy chain includes a gamma 1 chain, a gamma 2 chain, a gamma 3 chain, and a gamma 4 chain, which correspond to IgG1, IgG2, IgG3, and IgG4, respectively. When the heavy chain constituting the anti-hTfR antibody is a gamma chain, the gamma chain may be either a gamma 1 chain, a gamma 2 chain, a gamma 3 chain, and a gamma 4 chain, but is preferably a gamma 1 chain or a gamma 4 chain. When the anti-hTfR antibody is a humanized antibody or a human antibody and is an IgG, the light chain of the human antibody may be either a λ chain or a κ chain, and the heavy chain of the human antibody may be either a γ1 chain, a γ2 chain, a γ3 chain, or a γ4 chain, but is preferably a γ1 chain or a γ4 chain. For example, one embodiment of a preferred anti-hTfR antibody includes one in which the light chain is a λ chain and the heavy chain is a γ4 chain, and one in which the light chain is a λ chain and the heavy chain is a γ1 chain.
[0072] In the present invention, the drug (including a physiologically active protein) to be bound to the anti-hTfR antibody to form a conjugate is a drug to be made to function in muscle. Methods for binding the anti-hTfR antibody to such a drug include binding via a non-peptide linker or a peptide linker. As the non-peptide linker, polyethylene glycol, polypropylene glycol, a copolymer of ethylene glycol and propylene glycol, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ether, biodegradable polymers, lipid polymers, chitins, and hyaluronic acid, or derivatives thereof, or combinations thereof, can be used. The peptide linker is a peptide chain or derivatives thereof consisting of 1 to 50 amino acids bound by peptide bonds, and its N-terminus and C-terminus form covalent bonds with either the anti-hTfR antibody or the drug, respectively, thereby binding the anti-hTfR antibody to the drug.
[0073] The anti-hTfR antibody of the present invention and a drug are bound using PEG as a non-peptide linker, and are particularly referred to as anti-hTfR antibody-PEG-drug. The anti-hTfR antibody-PEG-drug can be produced by binding the anti-hTfR antibody to PEG to prepare an anti-hTfR antibody-PEG, and then binding the anti-hTfR antibody-PEG to the drug. Alternatively, the anti-hTfR antibody-PEG-drug can be produced by binding the drug to PEG to prepare a drug-PEG, and then binding the drug-PEG to the anti-hTfR antibody. When binding PEG to the anti-hTfR antibody and the drug, PEG modified with a functional group such as carbonate, carbonylimidazole, active ester of carboxylic acid, azlactone, cyclic imidothione, isocyanate, isothiocyanate, imidate, or aldehyde is used. The functional groups introduced into the PEG react mainly with amino groups in the anti-hTfR antibody and drug molecules, thereby covalently bonding the PEG to the hTfR antibody and drug. There are no particular limitations on the molecular weight and shape of the PEG used, but the average molecular weight (MW) is preferably MW=500-60000, more preferably MW=500-20000. For example, PEGs with average molecular weights of about 300, about 500, about 1000, about 2000, about 4000, about 10000, about 20000, etc. can be suitably used as non-peptide linkers.
[0074] For example, anti-hTfR antibody-PEG can be obtained by mixing anti-hTfR antibody with polyethylene glycol having an aldehyde group as a functional group (ALD-PEG-ALD) so that the molar ratio of ALD-PEG-ALD to the antibody is 11, 12.5, 15, 110, 120, etc., and adding a reducing agent such as NaCNBH3 to the mixture to cause a reaction. Next, anti-hTfR antibody-PEG can be reacted with a drug in the presence of a reducing agent such as NaCNBH3 to obtain an anti-hTfR antibody-PEG-drug. Conversely, anti-hTfR antibody-PEG-drug can also be obtained by first binding the drug to ALD-PEG-ALD to prepare a drug-PEG, and then binding the drug-PEG to an anti-hTfR antibody.
[0075] When the drug is a physiologically active protein (target protein), the anti-hTfR antibody and the target protein can be linked by peptide bonds to the N-terminus or C-terminus of the target protein, respectively, via a linker sequence or directly, to the C-terminus or N-terminus of the heavy or light chain of the anti-hTfR antibody. A fusion protein formed by linking an anti-hTfR antibody and a target protein in this manner can be obtained by incorporating a DNA fragment in which a cDNA encoding a target protein is placed in frame, either directly or with a DNA sequence encoding a linker sequence, at the 3'-terminus or 5'-terminus of the cDNA encoding the heavy or light chain of the anti-hTfR antibody, into an expression vector for mammalian cells, and culturing mammalian cells into which this expression vector has been introduced. In the case where a DNA fragment encoding a target protein is bound to a heavy chain, an expression vector for mammalian cells incorporating a cDNA fragment encoding the light chain of an anti-hTfR antibody is also introduced into the same host cell, and in the case where a DNA fragment encoding a target protein is bound to a light chain, an expression vector for mammalian cells incorporating a cDNA fragment encoding the heavy chain of an anti-hTfR antibody is also introduced into the same host cell. In the case where the anti-hTfR antibody is a single-chain antibody, a fusion protein in which the anti-hTfR antibody is bound to a target protein can be obtained by incorporating a DNA fragment in which a cDNA encoding a single-chain anti-hTfR antibody is linked to the 5'-end or 3'-end of the cDNA encoding the target protein, either directly or via a DNA sequence encoding a linker sequence, into an expression vector (for mammalian cells, eukaryotes such as yeast, or prokaryote cells such as E. coli), and expressing the DNA fragment in the cells in which the expression vector has been introduced. The fusion protein should be understood as one form of a conjugate.
[0076] A fusion protein of the type in which a target protein is bound to the C-terminus of the light chain of an anti-hTfR antibody is one in which the anti-human transferrin receptor antibody contains an amino acid sequence including all or part of the variable region of the light chain and an amino acid sequence including all or part of the variable region of the heavy chain, and the target protein is bound to the C-terminus of the light chain of this anti-human transferrin receptor antibody. Here, the light chain of the anti-hTfR antibody and the target protein may be bound directly or via a linker.
[0077] A fusion protein of the type in which a target protein is bound to the C-terminus of the heavy chain of an anti-hTfR antibody is one in which the anti-human transferrin receptor antibody contains an amino acid sequence including all or part of the variable region of the light chain and an amino acid sequence including all or part of the variable region of the heavy chain, and the target protein is bound to the C-terminus of the heavy chain of this anti-human transferrin receptor antibody. Here, the heavy chain of the anti-hTfR antibody and the target protein may be bound directly or via a linker.
[0078] A fusion protein of the type in which a target protein is bound to the N-terminus of the light chain of an anti-hTfR antibody is one in which the anti-human transferrin receptor antibody contains an amino acid sequence including all or part of the variable region of the light chain and an amino acid sequence including all or part of the variable region of the heavy chain, and the target protein is bound to the N-terminus of the light chain of this anti-human transferrin receptor antibody. Here, the light chain of the anti-hTfR antibody and the target protein may be bound directly or via a linker.
[0079] A fusion protein of the type in which a target protein is bound to the N-terminus of the heavy chain of an anti-hTfR antibody is one in which the anti-human transferrin receptor antibody contains an amino acid sequence including all or part of the variable region of the light chain and an amino acid sequence including all or part of the variable region of the heavy chain, and the target protein is bound to the N-terminus of the heavy chain of this anti-human transferrin receptor antibody. Here, the heavy chain of the anti-hTfR antibody and the target protein may be bound directly or via a linker.
[0080] In this case, the linker sequence placed between the anti-hTfR antibody and the target protein is a peptide chain composed of preferably 1 to 50, more preferably 1 to 17, even more preferably 1 to 10, and even more preferably 1 to 5 amino acids, but the number of amino acids constituting the linker sequence can be appropriately adjusted to 1, 2, 3, 1 to 17, 1 to 10, 10 to 40, 20 to 34, 23 to 31, 25 to 29, etc., depending on the target protein to be bound to the anti-hTfR antibody. Such a linker sequence is not limited in its amino acid sequence, so long as the anti-hTfR antibody linked thereto retains the affinity with hTfR and the target protein linked by the linker sequence can exert the physiological activity of the protein under physiological conditions, but is preferably composed of glycine and serine, for example, a sequence consisting of one amino acid of either glycine or serine, the amino acid sequence Gly-Ser, the amino acid sequence Gly-Gly-Ser, the amino acid sequence Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 3), the amino acid sequence Gly-Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 4), or a sequence consisting of 1 to 50 amino acids consisting of 1 to 10 or 2 to 5 consecutive amino acids of these amino acid sequences, a sequence consisting of 2 to 17, 2 to 10, 10 to 40, 20 to 34, 23 to 31, or 25 to 29 amino acids, etc. For example, a sequence having the amino acid sequence Gly-Ser can be suitably used as a linker sequence.
[0081] When the anti-hTfR antibody is a humanized antibody or a human antibody, the anti-hTfR antibody and the target protein can be bound to the N-terminus (or C-terminus) of the heavy or light chain of the anti-hTfR antibody by a peptide bond via a linker sequence or directly, respectively. When the target protein is bound to the N-terminus (or C-terminus) of the heavy chain of the anti-hTfR antibody, the C-terminus (or N-terminus) of the target protein is bound to the N-terminus (or C-terminus) of the γ-chain, μ-chain, α-chain, σ-chain or ε-chain of the anti-hTfR antibody by a peptide bond via a linker sequence or directly, respectively. When the target protein is bound to the N-terminus (or C-terminus) of the light chain of the anti-hTfR antibody, the C-terminus (or N-terminus) of the target protein is bound to the N-terminus (or C-terminus) of the λ-chain or κ-chain of the anti-hTfR antibody by a peptide bond via a linker sequence or directly, respectively. However, when the anti-hTfR antibody is composed of a Fab region or composed of a Fab region and all or part of the hinge region (Fab, F(ab')2, and F(ab')), the target protein can be bound to the N-terminus (or C-terminus) of the heavy chain or light chain constituting the Fab, F(ab')2, and F(ab'), respectively, via a linker sequence or directly, through a peptide bond at its C-terminus (or N-terminus).
[0082] In a fusion protein of an anti-hTfR antibody and a target protein, when the anti-hTfR antibody is a single-chain antibody, an amino acid sequence containing all or a part of the variable region of an immunoglobulin light chain and an amino acid sequence containing all or a part of the variable region of an immunoglobulin heavy chain are generally linked via a linker sequence. In this case, as long as the affinity of the anti-hTfR antibody to hTfR is maintained, a linker sequence may be linked to the C-terminus of an amino acid sequence derived from a light chain, and an amino acid sequence derived from a heavy chain may be further linked to the C-terminus of the linker sequence, or conversely, a linker sequence may be linked to the C-terminus of an amino acid sequence derived from a heavy chain, and an amino acid sequence derived from a light chain may be further linked to the C-terminus of the linker sequence. The same applies when the single-chain antibody is an scFv.
[0083] Here, the linker sequence disposed between the light chain and heavy chain of the immunoglobulin is a peptide chain composed of preferably 2 to 50 amino acids, more preferably 8 to 50 amino acids, even more preferably 10 to 30 amino acids, and even more preferably 12 to 18 amino acids or 15 to 25 amino acids, for example, 15 or 25 amino acids. There are no limitations on the amino acid sequence of such a linker sequence, so long as the anti-hTfR antibody formed by linking both chains by the linker retains affinity with hTfR and the target protein bound to the antibody can exhibit its physiological activity under physiological conditions, but preferably the linker sequence is composed of only glycine or glycine and serine, and for example, the amino acid sequence Gly-Ser, the amino acid sequence Gly-Gly-Ser, the amino acid sequence Gly-Gly-Gly, the amino acid sequence Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 3), the amino acid sequence Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 4), or a sequence consisting of 2 to 10 or 2 to 5 consecutive amino acids of these amino acid sequences. One preferred embodiment of the linker sequence is a sequence of 15 amino acids consisting of three consecutive amino acid sequences Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 3).
[0084] When the anti-hTfR antibody is a single-chain antibody, such a fusion protein can be produced, for example, by transforming a host cell such as a mammalian cell with an expression vector incorporating a DNA fragment having a base sequence encoding the fusion protein, and culturing the host cell.
[0085] In the present invention, when one peptide chain contains multiple linker sequences, for convenience, each linker sequence is named, in order from the N-terminus, as the first linker sequence, the second linker sequence, and so on.
[0086] There are no particular limitations on the target protein to be fused with the anti-hTfR antibody, so long as the protein is to function in muscle. A preferred target protein is, for example, a lysosomal enzyme encoded by a gene causing a lysosomal disease that causes muscle dysfunction. These lysosomal enzymes include, but are not limited to, human acid α-glucosidase (hGAA), human α-galactosidase A, α-L-iduronidase (IDUA), iduronate 2-sulfatase (IDS), glucocerebrosidase (GBA), β-galactosidase, GM2 activator protein, β-hexosaminidase A, β-hexosaminidase B, N-acetylglucosamine 1-phosphotransferase, α-mannosidase (LAMAN), β-mannosidase, galactosylceramidase (GALC), saposin C, arylsulfatase A (ARSA), α-L-fucosidase (FUCA1), aspartylglucosaminidase (ASG), and α-L-arginine activator protein (ALPHA). These include ceramidase, α-N-acetylgalactosaminidase, acid sphingomyelinase (ASM), β-glucuronidase (GUSB), heparan N-sulfatase (SGSH), α-N-acetylglucosaminidase (NAGLU), acetyl-CoA α-glucosaminide N-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase, acid ceramidase (AC), amylo-1,6-glucosidase, sialidase, aspartylglucosaminidase, palmitoyl protein thioesterase-1 (PPT-1), tripeptidyl peptidase-1 (TPP-1), hyaluronidase-1, CLN1, and CLN2.
[0087] The fusion protein of anti-hTfR antibody and lysosomal enzyme will be described in detail below, taking acid α-glucosidase and α-galactosidase A as examples.
[0088] When the fusion protein of anti-hTfR antibody and human acid α-glucosidase (hGAA) is administered to a patient with Pompe disease, it is taken up into the muscle cells of the patient and transported to the lysosomes. It then degrades glycogen accumulated in the lysosomes of the muscle cells of the patient with Pompe disease. In the case of Pompe disease, the target is muscle consisting mainly of skeletal muscle cells and muscle consisting mainly of cardiac muscle cells. The main symptom of Pompe disease is dysfunction of the cardiac muscle and skeletal muscle, but by administering this fusion protein, glycogen accumulated in the skeletal muscle cells and cardiac muscle cells is degraded, and various symptoms such as concentric cardiac hypertrophy, muscle weakness due to skeletal muscle invasion, and muscle hypotonia can be improved. In other words, the fusion protein of anti-hTfR antibody and human acid α-glucosidase can be used as a therapeutic agent for skeletal muscle dysfunction and / or cardiac damage in Pompe disease.
[0089] A specific preferred example of a fusion protein of an anti-hTfR antibody and human acid α-glucosidase is a fusion protein of human acid α-glucosidase and an anti-hTfR antibody, in which the light chain of the humanized anti-hTfR antibody has the amino acid sequence of SEQ ID NO: 24, and the heavy chain of the humanized anti-hTfR antibody is bound to human acid α-glucosidase at its C-terminus via the linker sequence Gly-Ser, and the fusion protein as a whole has the amino acid sequence shown in SEQ ID NO: 27.
[0090] There is also a fusion protein of human acid α-glucosidase and anti-hTfR antibody, which comprises a light chain of an anti-hTfR antibody having the amino acid sequence of SEQ ID NO: 24 and a heavy chain of an anti-hTfR antibody having the amino acid sequence of SEQ ID NO: 25, to which human acid α-glucosidase shown in SEQ ID NO: 1 is linked via the linker sequence Gly-Ser at the C-terminus.
[0091] When the fusion protein of anti-hTfR antibody and human α-galactosidase A (hα-GalA) is administered to a patient with Fabry disease, it is taken up into the muscle cells of the patient and transported to the lysosomes. It then degrades trihexosylceramide accumulated in the lysosomes of the muscle cells of the patient with Fabry disease. In the case of Fabry disease, the target is mainly muscle consisting of cardiac myocytes. Abnormalities in the cardiovascular system are observed in Fabry disease, but by administering this fusion protein, trihexosylceramide accumulated in cardiac myocytes is degraded, and various symptoms of cardiovascular abnormalities such as ventricular hypertrophy can be improved. This fusion protein is particularly effective in cardiac Fabry disease, which is an atypical type of Fabry disease in which the heart is mainly affected. In other words, the fusion protein of anti-hTfR antibody and human α-galactosidase A can be used as a therapeutic agent for cardiac disorders in Fabry disease, especially cardiac Fabry disease.
[0092] A specific preferred example of a fusion protein of anti-hTfR antibody and human α-galactosidase A is a fusion protein of human α-galactosidase A and anti-hTfR antibody, in which the light chain of the humanized anti-hTfR antibody has the amino acid sequence of SEQ ID NO: 24, and the heavy chain of the humanized anti-hTfR antibody is bound to human α-galactosidase A at its C-terminus via the linker sequence Gly-Ser, and the fusion protein as a whole has the amino acid sequence shown in SEQ ID NO: 29.
[0093] There is also a fusion protein of human α-galactosidase A and an anti-hTfR antibody, which comprises a light chain of an anti-hTfR antibody having the amino acid sequence of SEQ ID NO: 24 and a heavy chain of an anti-hTfR antibody having the amino acid sequence of SEQ ID NO: 25, to which human α-galactosidase A shown in SEQ ID NO: 2 is linked via the linker sequence Gly-Ser to the C-terminus thereof.
[0094] The conjugate of the present invention, in which the anti-hTfR antibody and a drug are bound, can be used as a pharmaceutical composition to be administered into the blood and to exert its medicinal effect in the muscle. Such drugs are generally administered to patients by intravenous injection such as intravenous drip infusion, subcutaneous injection, or intramuscular injection, but there is no particular limitation on the administration route.
[0095] The conjugate of the present invention in which the anti-hTfR antibody and a drug are bound can be supplied to medical institutions as a pharmaceutical composition in the form of a lyophilized product, an aqueous liquid, or the like. In the case of an aqueous liquid, the pharmaceutical composition can be supplied as a formulation in which the pharmaceutical composition is pre-dissolved in a solution containing a stabilizer, a buffer, and an isotonicity agent and sealed in a vial or syringe. A formulation sealed in a syringe is generally called a pre-filled syringe formulation. By making it a pre-filled syringe formulation, it is possible to simplify administration of the drug by the patient himself.
[0096] When supplied as an aqueous liquid, the concentration of the conjugate contained in the aqueous liquid should be adjusted appropriately depending on the dosage and administration, and is, for example, 1 to 4 mg / mL. The stabilizer contained in the aqueous liquid is not particularly limited as long as it is pharma- ceutical acceptable, but a nonionic surfactant is preferably used. As such a nonionic surfactant, polysorbate, poloxamer, etc. can be used alone or in combination. As the polysorbate, polysorbate 20 and polysorbate 80 are particularly suitable, and as the poloxamer, poloxamer 188 (polyoxyethylene (160) polyoxypropylene (30) glycol) is particularly suitable. In addition, the concentration of the nonionic surfactant contained in the aqueous liquid is preferably 0.01 to 1 mg / mL, more preferably 0.01 to 0.5 mg / mL, and even more preferably 0.1 to 0.5 mg / mL. Amino acids such as histidine, arginine, methionine, and glycine can also be used as stabilizers. When used as a stabilizer, the concentration of the amino acid contained in the aqueous liquid is preferably 0.1 to 40 mg / mL, more preferably 0.2 to 5 mg / mL, and even more preferably 0.5 to 4 mg / mL. The buffer contained in the aqueous liquid is not particularly limited as long as it is pharma- ceutical acceptable, but a phosphate buffer is preferred, and sodium phosphate buffer is particularly preferred. When sodium phosphate buffer is used as the buffer, the concentration of sodium phosphate is preferably 0.01 to 0.04 M. The pH of the aqueous liquid adjusted by the buffer is preferably 5.5 to 7.2. The isotonicity agent contained in the aqueous liquid is not particularly limited as long as it is pharma-ceutical acceptable, but sodium chloride and mannitol can be suitably used alone or in combination as the isotonicity agent. EXAMPLES
[0097] The present invention will be described in more detail below with reference to examples, but it is not intended that the present invention be limited to the examples.
[0098] [Example 1] Construction of a vector for expressing hTfR Using human spleen Quick Clone cDNA (Clontech) as a template, a gene fragment encoding human transferrin receptor (hTfR) was amplified by PCR using primers hTfR5' (SEQ ID NO: 7) and hTfR3' (SEQ ID NO: 8). The amplified gene fragment encoding hTfR was digested with MluI and NotI and inserted between MluI and NotI of pCI-neo vector (Promega). The resulting vector was named pCI-neo(hTfR). Next, this vector was digested with MluI and NotI to excise the gene fragment encoding hTfR, and inserted between MluI and NotI of pE-mIRES-GS-puro, an expression vector described in International Publication WO2012 / 063799, to construct pE-mIRES-GS-puro(hTfR), an expression vector for hTfR.
[0099] [Example 2] Construction of recombinant hTfR After transfecting CHO-K1 cells with pE-mIRES-GS-puro(hTfR) by electroporation, the cells were incubated with CD OptiCHO containing methionine sulfoximine (MSX) and puromycin. TM The cells were selectively cultured using a medium (Invitrogen) to obtain recombinant hTfR-expressing cells, which were then cultured to prepare recombinant hTfR.
[0100] Example 3: Immunization of mice with recombinant hTfR Mice were immunized using as an antigen the recombinant hTfR prepared in Example 2. Immunization was performed by intravenously or intraperitoneally administering the antigen to the mice.
[0101] [Example 4] Preparation of hybridomas Approximately one week after the final antigen administration, the mouse spleen was removed and homogenized to separate splenocytes. The resulting splenocytes were fused with a mouse myeloma cell line (P3.X63.Ag8.653) using the polyethylene glycol method. After cell fusion, the cells were suspended in RPMI1640 medium containing (1X) HAT supplement (Life Technologies) and 10% Ultra low IgG fetal bovine serum (Life Technologies), and the cell suspension was dispensed into 20 96-well plates at 200 μL / well. After culturing the cells in a carbon dioxide incubator (37°C, 5% CO2) for 10 days, each well was observed under a microscope and wells containing a single colony were selected. When the cells in each well became nearly confluent, the culture supernatant was collected and used as the hybridoma culture supernatant for the following screening.
[0102] [Example 5] Screening of high affinity antibody producing cell lines The recombinant hTfR solution (Sino Biologics) was diluted with 50 mM sodium carbonate buffer (pH 9.5-9.6) to a concentration of 5 μg / mL, which was used as the solid-phase solution. TM 50 μL of the solution was added to each well of a flat-bottom 96-well plate (base material: polystyrene, Nunc), and the plate was left to stand at room temperature for 1 hour to allow the recombinant hTfR to be adsorbed and immobilized on the plate. The solid phase solution was discarded, and each well was washed three times with 250 μL of washing solution (PBS-T: PBS containing 0.05% Tween20), after which 200 μL of blocking solution (PBS containing 1% BSA) was added to each well, and the plate was left to stand at room temperature for 1 hour.
[0103] The blocking solution was discarded, and each well was washed three times with 250 μL of PBS-T. Then, 50 μL of hybridoma culture supernatant was added to each well, and the plate was left to stand at room temperature for 1 hour to allow the mouse anti-hTfR antibody contained in the culture supernatant to bind to the recombinant hTfR. At this time, as a control, 50 μL of culture supernatant of a hybridoma that does not produce mouse anti-hTfR antibody was added to the well. In addition, 50 μL of hybridoma culture medium was added to the well next to each culture supernatant, and this was used as a mock well. Measurements were performed with n=2. Next, the solution was discarded, and each well was washed three times with 250 μL of PBS-T.
[0104] 100 μL of HRP-labeled goat anti-mouse immunoglobulin antibody solution (Promega) was added to each well, and the plate was left to stand at room temperature for 1 minute. The solution was then discarded, and each well was washed three times with 250 μL of PBS-T. Next, 50 μL of color-developing substrate solution TMB Stabilized Substrate for Horseradish Peroxidase (Promega) was added to each well, and the plate was left to stand at room temperature for 10 to 20 minutes. Next, 100 μL of stopping solution (2 N sulfuric acid) was added to each well, and the absorbance at 450 nm of each well was measured using a plate reader. The average value of the two wells for each culture supernatant and control was taken, and the average value of the two mock wells placed for each culture supernatant and control was subtracted from these average values to obtain the measured value.
[0105] Fourteen types of hybridoma cells corresponding to the culture supernatants added to the wells that showed high measurement values were selected as cell lines (high-affinity antibody-producing cell lines) that produce antibodies that show high affinity for hTfR (high-affinity anti-hTfR antibodies). These 14 cell lines were numbered Clone 1 to Clone 14. The anti-hTfR antibodies produced by Clone 1 to Clone 14 were designated Anti-hTfR Antibody No. 1 to Anti-hTfR Antibody No. 14, respectively.
[0106] [Example 6] Analysis of amino acid sequences in the variable regions of high-affinity anti-hTfR antibodies Clone strain 3 was further selected from clone strain 1 to clone strain 14 selected in Example 5. cDNA of clone strain 3 was prepared, and genes encoding the light and heavy chains of the antibody were amplified using this cDNA as a template. The base sequence of the amplified gene was translated, and the amino acid sequences of the variable regions of the light and heavy chains of anti-hTfR antibody No. 3 produced by this cell strain were determined.
[0107] Anti-hTfR antibody No. 3 contained the amino acid sequence shown in SEQ ID NO: 9 in the variable region of the light chain and the amino acid sequence shown in SEQ ID NO: 10 in the variable region of the heavy chain. The variable region of the light chain contained the amino acid sequences shown in SEQ ID NO: 11 or 12 in CDR1, SEQ ID NO: 13 or 14 in CDR2, and SEQ ID NO: 15 in CDR3, while the variable region of the heavy chain contained the amino acid sequences shown in SEQ ID NO: 16 or 17 in CDR1, SEQ ID NO: 18 or 19 in CDR2, and SEQ ID NO: 20 or 21 in CDR3. However, it was considered that the CDRs are not limited to the above amino acid sequences, and that regions containing these amino acid sequences and amino acid sequences consisting of three or more consecutive amino acids containing a part of these amino acid sequences can also be CDRs.
[0108] [Example 7] Measurement of affinity of anti-hTfR antibodies to human TfR and monkey TfR The affinity of anti-hTfR antibodies to human TfR and monkey TfR was measured using OctetRED96 (ForteBio, a division of Pall Corporation), a biomolecular interaction analysis system using BioLayer Interferometry (BLI). The basic principle of BioLayer Interferometry is briefly explained below. When light of a specific wavelength is projected onto a layer of biomolecules immobilized on the surface of a sensor chip, the light is reflected from the two surfaces of the biomolecular layer and the internal reference layer, generating an optical interference wave. When molecules in the measurement sample bind to the biomolecules on the surface of the sensor chip, the thickness of the layer at the tip of the sensor increases, causing a wavelength shift in the interference wave. By measuring the change in this wavelength shift, the number of molecules that bind to the biomolecules immobilized on the surface of the sensor chip can be quantified and kinetically analyzed in real time. The measurements were performed generally according to the operation manual attached to the OctetRED96. The human TfR used was a recombinant human TfR (rhuman TfR: Sino Biological Co.) with an N-terminal histidine tag added and an amino acid sequence of the extracellular domain of hTfR from the 89th cysteine residue from the N-terminus to the phenylalanine at the C-terminus in the amino acid sequence shown in SEQ ID NO: 1. The monkey TfR used was a recombinant monkey TfR (rmonkey TfR: Sino Biological Co.) with an N-terminal histidine tag added and an amino acid sequence of the extracellular domain of cynomolgus monkey TfR from the 89th cysteine residue from the N-terminus to the phenylalanine at the C-terminus in the amino acid sequence shown in SEQ ID NO: 2.
[0109] The three clones selected in Example 6 were cultured at a cell concentration of approximately 2 x 10 5The cells were diluted with RPMI1640 medium containing (1X) HAT supplement (Life Technologies) and 10% Ultra Low IgG fetal bovine serum (Life Technologies) to a concentration of 100 cells / mL, and 200 mL of the cell suspension was added to a 1 L Erlenmeyer flask and cultured at 37°C in a humidified environment of 5% CO2 and 95% air at an agitation speed of approximately 70 rpm for 6 to 7 days. The culture supernatant was collected by centrifugation and filtered through a 0.22 μm filter (Millipore) to obtain the culture supernatant. The collected culture supernatant was loaded onto a Protein G column (column volume: 1 mL, GE Healthcare) that had been equilibrated with 3 column volumes of 20 mM Tris buffer (pH 8.0) containing 150 mM NaCl. The column was then washed with 5 times the column volume of the same buffer, after which the adsorbed antibody was eluted with 4 times the column volume of 50 mM glycine buffer (pH 2.8) containing 150 mM NaCl, and the eluted fraction was collected. 1 M Tris buffer (pH 8.0) was added to the eluted fraction to adjust the pH to 7.0. This was used in the following experiments as a purified preparation of anti-hTfR antibody No. 3.
[0110] The purified anti-hTfR antibody No. 3 was diluted in two steps with HBS-P+ (10 mM HEPES containing 150 mM NaCl, 50 μM EDTA, and 0.05% Surfactant P20) to prepare antibody solutions with seven concentrations ranging from 0.78125 to 50 nM (0.117 to 7.5 μg / mL). These antibody solutions were used as sample solutions. rHuman TfR and rMonkey TfR were each diluted with HBS-P+ to prepare 25 μg / mL solutions, which were used as rHuman TfR-ECD (Histag) solutions and rMonkey TfR-ECD (Histag) solutions, respectively.
[0111] The sample solution prepared by the above two-step dilution was added to a 96-well plate, black (Greiner Bio-One) at 200 μL / well. The rHuman TfR-ECD (Histag) solution and rMonkey TfR-ECD (Histag) solution prepared above were added to the designated wells at 200 μL / well. HBS-P+ was added to the baseline, dissociation, and washing wells at 200 μL / well. 10 mM Glycine-HCl (pH 1.7) was added to the regeneration wells at 200 μL / well. 0.5 mM NiCl2 solution was added to the activation wells at 200 μL / well. This plate and a biosensor (Biosensor / Ni-NTA: ForteBio, a division of Pall Corporation) were placed in the designated positions of the OctetRED96.
[0112] After operating OctetRED96 under the conditions shown in Table 1 below to obtain data, the binding reaction curve was fitted to a 1:1 binding model or a 2:1 binding model using the analysis software attached to OctetRED96, and the association rate constant (kon) and dissociation rate constant (koff) of the anti-hTfR antibody to rhuman TfR and rmonkey TfR were measured, and the dissociation constant (K D The measurements were carried out at temperatures between 25 and 30°C.
[0113] [Table 1]
[0114] The dissociation constant (K D ) is 1X10 -12 The dissociation constant (K D ) is 1X10 -12 These results indicate that anti-hTfR antibody No. 3 has high affinity not only for human TfR but also for monkey TfR.
[0115] [Example 8] Preparation of humanized anti-hTfR antibody An attempt was made to humanize the amino acid sequences contained in the variable regions of the light and heavy chains of anti-hTfR antibody No. 3. As a result, a humanized light chain variable region having the amino acid sequence shown in SEQ ID NO: 22 and a humanized heavy chain variable region having the amino acid sequence shown in SEQ ID NO: 23 were obtained. Furthermore, for the light chain, a light chain having the amino acid sequence shown in SEQ ID NO: 24, which has the amino acid sequence shown in SEQ ID NO: 22 in its variable region, was obtained. For the heavy chain, a heavy chain having the amino acid sequence shown in SEQ ID NO: 25, which has the amino acid sequence shown in SEQ ID NO: 23 in its variable region, was obtained. The heavy chain having the amino acid sequence shown in SEQ ID NO: 25 is of the IgG4 type. The dissociation constant (K D ) was measured by the method described in Example 7. As a result, the dissociation constant (K D ) is 1X10 -12 The dissociation constant (K D ) is about 1X10 -9 These results demonstrate that the obtained humanized anti-hTfR antibody No. 3 has high affinity not only for human TfR but also for monkey TfR.
[0116] Example 9: Construction of a gene encoding a fusion protein of an anti-TfR antibody and hGAA A DNA fragment (SEQ ID NO: 26) was synthesized that encodes a light chain having the amino acid sequence shown in SEQ ID NO: 24. This DNA fragment has, in order from the 5' end, an MluI sequence and a sequence encoding a leader peptide that functions as a secretion signal on the 5' side, and a NotI sequence on the 3' side.
[0117] Also, a DNA fragment (SEQ ID NO: 28) was synthesized that codes for a protein having an amino acid sequence as a whole shown in SEQ ID NO: 27, in which human acid α-glucosidase having the amino acid sequence shown in SEQ ID NO: 1 is bound via a linker sequence consisting of Gly-Ser to the C-terminus of the heavy chain of the amino acid sequence shown in SEQ ID NO: 25. This DNA fragment has, in order from the 5' end, an MluI sequence and a sequence encoding a leader peptide that functions as a secretion signal on the 5' side, and a NotI sequence on the 3' side.
[0118] [Example 10: Construction of expression vector for fusion protein of anti-TfR antibody and hGAA] The pEF / myc / nuc vector (Invitrogen) was digested with KpnI and NcoI to excise the region containing the EF-1α promoter and its first intron, and the end was blunted with T4 DNA polymerase. pCI-neo (Invitrogen) was digested with BglII and EcoRI to excise the region containing the CMV enhancer / promoter and intron, and then blunted with T4 DNA polymerase. The above-mentioned region containing the EF-1α promoter and its first intron was inserted into this to construct the pE-neo vector. The pE-neo vector was digested with SfiI and BstXI to excise a region of about 1 kbp containing the neomycin resistance gene. The hygromycin gene was amplified by PCR using pcDNA3.1 / Hygro(+) (Invitrogen) as a template and primers Hyg-Sfi5' (sequence number 30) and Hyg-BstX3' (sequence number 31). The amplified hygromycin gene was digested with SfiI and BstXI and inserted into the pE-neo vector from which the neomycin resistance gene had been excised to construct the pE-hygr vector.
[0119] The pE-hygr vector and the pE-neo vector were digested with MluI and NotI, respectively. The DNA fragment (SEQ ID NO: 26) encoding the light chain of the anti-hTfR antibody synthesized in Example 9 and the DNA fragment (SEQ ID NO: 28) encoding the protein in which the heavy chain of the anti-hTfR antibody and human acid α-glucosidase are bound were digested with MluI and NotI and inserted between the MluI and NotI sites of the pE-hygr vector and the pE-neo vector, respectively. The resulting vectors were designated pE-hygr (LC), a vector for expressing the light chain of the humanized anti-hTfR antibody, and pE-neo (HC-hGAA), a vector for expressing the protein in which the heavy chain of the anti-hTfR antibody and human acid α-glucosidase are bound.
[0120] Example 11: Preparation of cells for expressing hGAA-humanized anti-hTfR antibody fusion protein CHO cells (CHO-K1: obtained from the American Type Culture Collection) were transformed with pE-hygr (LC) and pE-neo (HC-hGAA) constructed in Example 10 using a GenePulser (Bio-Rad) according to the following method. The transformation of cells was generally carried out as follows. 5 CHO-K1 cells were cultured using CD OptiCHO TM The cells were seeded on a 3.5 cm culture dish containing medium (Life Technologies) and cultured overnight at 37°C in 5% CO2. The medium was replaced with Opti-MEM TM The medium was replaced with I medium (Life Technologies), and the cells were cultured at 5 × 10 6 The cells were suspended at a density of 100 cells / mL. 100 μL of the cell suspension was taken and added to Opti-MEM TM 5 μL of pE-hygr (LC1) and pE-neo (HC1) plasmid DNA solutions diluted to 100 μg / mL in I medium were added to each well. Electroporation was performed using a GenePulser (Bio-Rad) to introduce the plasmids into the cells. The cells were cultured overnight at 37°C under 5% CO2 conditions, and then incubated in CD OptiCHO medium supplemented with 0.5 mg / mL hygromycin and 0.8 mg / mL G418.TM The cells were selectively cultured in medium.
[0121] Next, the cells selected by selective culture were seeded on a 96-well plate by limiting dilution so that one or less cell was seeded per well, and cultured for about 10 days so that each cell formed a monoclonal colony. The culture supernatant of the well in which a monoclonal colony had formed was collected, and the humanized antibody content in the culture supernatant was examined by ELISA, and a cell line with high expression of the hGAA-humanized anti-hTfR antibody fusion protein was selected.
[0122] The ELISA method was generally carried out as follows. 100 μL of a goat anti-human IgG polyclonal antibody solution diluted to 4 μg / mL with 0.05 M bicarbonate buffer (pH 9.6) was added to each well of a 96-well microtiter plate (Nunc), and the plate was left to stand at room temperature for at least 1 hour to allow the antibody to be adsorbed to the plate. Next, each well was washed three times with PBS-T, and then 200 μL of Starting Block (PBS) Blocking Buffer (Thermo Fisher Scientific) was added to each well, and the plate was left to stand at room temperature for 30 minutes. Each well was washed three times with PBS-T, and then 100 μL of culture supernatant or human IgG standard diluted to an appropriate concentration with PBS-BT (PBS with 0.5% BSA and 0.05% Tween 20) was added to each well, and the plate was left to stand at room temperature for at least 1 hour. After washing the plate three times with PBS-T, 100 μL of HRP-labeled anti-human IgG polyclonal antibody solution diluted with PBS-BT was added to each well, and the plate was left at room temperature for at least 1 hour. After washing each well three times with PBS-T, 100 μL of 0.4 mg / mL o-phenylenediamine containing phosphate-citrate buffer (pH 5.0) was added to each well, and the plate was left at room temperature for 8 to 20 minutes. Next, 100 μL of 1 mol / L sulfuric acid was added to each well to stop the reaction, and the absorbance at 490 nm of each well was measured using a 96-well plate reader. The cells corresponding to the wells that showed high measured values were determined to be cell lines that highly express hGAA-humanized anti-hTfR antibody fusion protein. The fusion protein of hGAA and humanized anti-hTfR antibody expressed by this cell line was determined to be hGAA-anti-hTfR antibody.
[0123] [Example 12] Production of hGAA-anti-hTfR antibody The hGAA-anti-hTfR antibody was produced by the following method. The hGAA-anti-hTfR antibody highly expressing strain obtained in Example 11 was cultured at a cell concentration of about 2 × 10 5 CD OptiCHO TMThe cells were diluted with the medium, and 200 mL of the cell suspension was added to a 1 L Erlenmeyer flask and cultured at 37°C in a humidified environment consisting of 5% CO2 and 95% air at an agitation speed of approximately 70 rpm for 6 to 7 days. The culture supernatant was collected by centrifugation and filtered through a 0.22 μm filter (Millipore) to obtain the culture supernatant. The collected culture supernatant was added with 20 mM Tris buffer (pH 8.0) containing 150 mL NaCl, which is 5 times the column volume, and loaded onto a Protein A column (column volume: 1 mL, Bio-Rad) that had been previously equilibrated with 20 mM Tris buffer (pH 8.0) containing 150 mM NaCl, which is 3 times the column volume. The column was then washed with 5 times the column volume of the same buffer, and the adsorbed hGAA-anti-hTfR antibody was eluted with 4 times the column volume of 50 mM glycine buffer (pH 2.8) containing 150 mM NaCl. The pH of the eluate containing the hGAA-anti-hTfR antibody was adjusted to pH 7.0 by adding 1 M Tris buffer (pH 8.0), and then the buffer was exchanged into PBS using an Amicon Ultra 30 kDa membrane (Millipore). This was used as the purified hGAA-anti-hTfR antibody preparation.
[0124] [Example 13] Measurement of the amount of hGAA uptake into cells using human skeletal muscle Human skeletal muscle cells (PromoCell) were cultured at 8.0 x 10 in Skeletal Muscle Cell Growth Medium (Ready-to-use) (PromoCell). 4 Dilute to 500 / mL and place 250μL in Cellnest TMThe cells are seeded into each well of a 96-well plate coated with 100 μL of 100% glycerol (Fujifilm). After culturing for 3 days at 37°C under 5% CO2, the medium is replaced with Skeletal Muscle Cell Differentiation Medium (Ready-to-use) (PromoCell). The medium is then replaced with differentiation induction medium every 2 days, and differentiation is induced for 6 days. After removing the medium, 100 μL of each of the hGAA-anti-hTfR antibody and serial dilutions of hGAA (0.005-20.0 μg / mL) prepared using differentiation induction medium are added to each well as test substances, and the cells are further cultured at 37°C under 5% CO2 for 20 hours.
[0125] After incubation, remove the medium and wash each well three times with 300 μL of PBS. TM Add 100 μL of PBS-BT (with 0.5% Protease Inhibitor Cocktail, Thermo Fisher Scientific) to each well and shake on a plate shaker at room temperature for 25 minutes to prepare cell extracts. Take 20 μL of extract from each well and quantify the protein contained in the extract using a BCA protein assay kit (Pierce). After taking 20 μL of extract, add 80 μL of PBS-BT to each well and shake on a plate shaker at room temperature for 10 minutes to prepare cell extracts for ELISA measurement.
[0126] Prepare cell extracts in the same manner from cells in wells to which no test substance was added, and use these as pooled extracts. Serial dilutions of hGAA-anti-hTfR antibody and commercially available medical hGAA are made with the pooled extract to prepare calibration curve samples. Test substances can be quantified using the following ELISA method.
[0127] Rabbit anti-hGAA polyclonal antibodies obtained by immunizing rabbits with hGAA were diluted to 5 μg / mL with 20 mmol / L sodium carbonate buffer (pH 9.0) and 100 μL of each antibody was placed in a 96-well plate (Maxisorp TM) into each well and shake on a plate shaker at room temperature for 1 hour. Remove the antibody solution and add 300 μL of blocking buffer (PBS containing 1% BSA) to each well and leave to stand at room temperature for 1 hour. Next, wash each well three times with 300 μL of PBS-T. Next, add 100 μL each of the calibration curve sample and each cell extract to each well and shake on a plate shaker at room temperature for 1 hour. After washing each well three times with 300 μL of washing solution, add 100 μL of biotin-labeled rabbit anti-hGAA antibody (prepared in-house) prepared in PBS-BT to each well and shake on a plate shaker at room temperature for 1 hour. After washing each well three times with 300 μL of washing solution, add 100 μL of NeutrAvidin-HRP conjugate (Pierce) diluted with 0.5% BSA / PBS (with 0.05% Tween20) to each well, shake on a plate shaker at room temperature for 15 minutes, and then wash each well three times with 300 μL of washing solution. Add 100 μL of an equal mixture of TMB Peroxidase Substrate and TMB Peroxidase Substrate Solution B from TMB Microwell Peroxidase Substrate (2-Component System, KPL) to each well and allow the color reaction to develop at room temperature. After sufficient color development is achieved, add 100 μL of 1 mol / L phosphoric acid to each well to stop the reaction. The absorbance at a wavelength of 450 nm is measured using a microplate reader, and a calibration curve is prepared using SoftMax Pro (Molecular Devices), and the measured values of each test substance are interpolated to calculate the concentration of each test substance. The test substance concentration of each cell extract is divided by the protein concentration to obtain the amount of test substance taken up into cells (ng / mg protein).
[0128] [Example 14] Generation of CD71-KI / GAA-KO mice CD71-KI / GAA-KO mice, in which the acid α-glucosidase gene (GAA gene) was knocked out and the human transferrin receptor gene (CD71 gene) was knocked in, were generated by a general genetic engineering technique. The construction method is roughly as follows. A targeting vector (GAA knockout vector) capable of knocking out the mouse GAA gene was constructed by inserting a stop codon and a neomycin resistance gene into the BamHI site present in exon 6 of the mouse GAA gene. This targeting vector contains the base sequence shown in SEQ ID NO: 32. After linearization of the targeting vector, it was introduced into C57BL / 6 strain ES cells by electroporation. After introduction, selective culture was performed using neomycin drug resistance as an indicator to obtain drug-resistant ES clones. The obtained drug-resistant ES clones were screened by genomic PCR and Southern blotting, and clones in which specific homologous recombination had been established (homologous recombination ES clones) were selected. We generated chimeric embryos by aggregation using homologous recombination ES clones and 8-cell embryos of ICR strains. We transplanted the chimeric embryos into recipient mice and allowed them to give birth to chimeric mice.
[0129] The chimeric mice were naturally mated to produce GAA-KO heterozygous mice, which were then further mated to produce GAA-KO homozygous mice. CD71-KI heterozygous mice were mated with GAA-KO homozygous mice, and the resulting mice were screened to produce CD71-KI / GAA-KO mice. CD71-KI heterozygous mice were produced according to the method described in Sonoda H., et al. Molecular Therapy 26. 1366-74 (2018).
[0130] [Example 15] Measurement of the amount of hGAA uptake into cells using mice The purified hGAA-anti-hTfR antibody product prepared in Example 12 and commercially available medical hGAA were each made into a 4 mg / mL solution using physiological saline. Using these solutions, hGAA-anti-hTfR antibody and hGAA were each administered to CD71-KI / GAA-KO mice via the tail vein. Both hGAA-anti-hTfR antibody and hGAA were administered at a dose of 20 mg per administration, a total of four times every other week. Two weeks after the last administration, the mice were killed by exsanguination, and the heart, diaphragm, soleus muscle, tibialis anterior muscle, and quadriceps muscle were collected. The collected tissues were washed with physiological saline. The glycogen concentration (mg / g wet tissue weight) contained in these muscle tissues was measured by the method described in Example 16. The group administered with hGAA-anti-hTfR antibody was the hGAA-anti-hTfR antibody administration group, and the group administered with commercially available medical hGAA was the hGAA administration group. In addition, CD71-KI / GAA-KO mice were administered an equal volume of saline to serve as the KO control group, and wild-type mice were administered an equal volume of saline to serve as the wild-type control group. Each group contained five mice.
[0131] The measurement results of the amount of glycogen contained in each muscle tissue are shown in Figures 1 to 5. Figure 1 shows the heart, Figure 2 shows the diaphragm, Figure 3 shows the soleus muscle, Figure 4 shows the tibialis anterior muscle, and Figure 5 shows the quadriceps muscle. When the amount of glycogen contained in each muscle tissue in the hGAA administration group is taken as 100%, the amount of glycogen contained in each muscle tissue in the hGAA-anti-hTfR antibody administration group was reduced to approximately 7.5% in the heart, approximately 6.5% in the diaphragm, approximately 13.5% in the soleus muscle, approximately 13.5% in the tibialis anterior muscle, and approximately 6% in the quadriceps muscle. These results indicate that hGAA-anti-hTfR antibody can efficiently break down the amount of glycogen accumulated in muscle tissue compared to commercially available medical hGAA. Pompe disease (glycogen storage disease type II) is a disease in which glycogen accumulates in large amounts in the lysosomes of cells due to a genetic deficiency in most or all of the acid α-glucosidase activity, and the main symptoms are dysfunction of the cardiac and skeletal muscles. In other words, hGAA-anti-hTfR antibody can more efficiently decompose glycogen accumulated in the cardiac and skeletal muscles of Pompe disease patients than hGAA, and is therefore a promising therapeutic agent for enzyme replacement therapy in Pompe disease patients.
[0132] [Example 16] Method for measuring the amount of glycogen contained in tissue The tissue obtained in Example 15 and 15 SUS beads with a diameter of 0.5 mm were placed in a holder set in a bead crusher (BEADS CRUSHER μT-12, Taitec Co., Ltd.), and water for injection was added. The tissue was crushed by operating the bead crusher. The resulting tissue crushed material was centrifuged at 15,000 rpm for 10 minutes at 4°C, and the supernatant was collected as a sample solution and frozen until measurement.
[0133] Glycogen concentration was measured using a Glycogen Colorimetric / Fluorometric Assay Kit (Biovision) in the following general procedure. The standard curve sample (Glycogen Standard) was diluted stepwise with pure water, and 50 μL of this dilution was added to each well of an F96 Black plate (Nunc). Similarly, 50 μL of the sample solution was added to each well. At this time, each standard curve sample dilution and sample solution were added to two wells. 1 μL of Hydrolysis Enzyme Mix was added to each of the two wells containing the standard curve sample and the one well containing the sample, and the mixture was reacted at room temperature for 30 minutes to decompose glycogen into glucose. Furthermore, 50 μL of Reaction Mix containing a fluorescent reagent was added to each of all wells, and the mixture was reacted at room temperature for 30 minutes in the dark. Fluorescence intensity was measured (Ex / Em = 535 / 587 nm) using a fluorescence plate reader (SPECTRA max GEMINI XPS, Molecular Devices), and the glucose concentrations of the sample solutions with and without Hydrolysis Enzyme Mix were calculated from a calibration curve created by a linear fit curve based on the theoretical concentration (X) and average signal value (Y) of the calibration curve sample. Next, the glucose concentration of the sample solution without Hydrolysis Enzyme Mix was subtracted from the measured glucose concentration of the sample solution with Hydrolysis Enzyme Mix, and this value was used as the glycogen concentration of the sample solution. The glycogen concentration of each tissue (mg / g wet tissue weight) was calculated from the weight of the tissue used to prepare the sample solution and the calculated glycogen concentration. [Industrial Applicability]
[0134] According to the present invention, a drug that should function in muscle but is not sufficiently taken up by muscle as it is can be made into a conjugate with an anti-transferrin receptor antibody so that it can be efficiently taken up by muscle, which can be applied to the development of new therapeutic drugs for muscle diseases. In addition, by making a protein that needs to be administered in large amounts to function in muscle, such as hGAA, into a fusion protein using the present invention, the dosage can be significantly reduced, which has medical economic benefits. [Sequence List Free Text]
[0135] SEQ ID NO: 3: Amino acid sequence of linker example 1 SEQ ID NO: 4: Amino acid sequence of linker example 2 SEQ ID NO: 7: Primer hTfR5', synthetic sequence SEQ ID NO: 8: Primer hTfR3', synthetic sequence SEQ ID NO: 9: Amino acid sequence of the variable region of the light chain of mouse anti-hTfR antibody No. 3 SEQ ID NO: 10: Amino acid sequence of the variable region of the heavy chain of mouse anti-hTfR antibody No. 3 SEQ ID NO: 11: Amino acid sequence of the light chain CDR1 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 12: Amino acid sequence 2 of the light chain CDR1 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 13: Amino acid sequence of the light chain CDR2 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 14: Amino acid sequence 2 of the light chain CDR2 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 15: Amino acid sequence of the light chain CDR3 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 16: Amino acid sequence of heavy chain CDR1 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 17: Amino acid sequence 2 of heavy chain CDR1 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 18: Amino acid sequence of the heavy chain CDR2 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 19: Amino acid sequence 2 of the heavy chain CDR2 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 20: Amino acid sequence 1 of the heavy chain CDR3 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 21: Amino acid sequence 2 of the heavy chain CDR3 of mouse anti-hTfR antibody No. 3 SEQ ID NO: 22: Amino acid sequence of the variable region of the light chain of humanized anti-hTfR antibody No. 3 SEQ ID NO: 23: Amino acid sequence of the variable region of the heavy chain of humanized anti-hTfR antibody No. 3 SEQ ID NO: 24: Amino acid sequence of the light chain of humanized anti-hTfR antibody No. 3 SEQ ID NO: 25: Amino acid sequence of the heavy chain of humanized anti-hTfR antibody No. 3 SEQ ID NO: 26: Nucleotide sequence encoding the amino acid sequence of the light chain of humanized anti-hTfR antibody No. 3, synthetic sequence SEQ ID NO: 27: Amino acid sequence of the fusion protein of the heavy chain of humanized anti-hTfR antibody No. 3 and hGAA SEQ ID NO: 28: A base sequence encoding the amino acid sequence of the fusion protein of the heavy chain of humanized anti-hTfR antibody No. 3 and hGAA, a synthetic sequence SEQ ID NO: 29: Amino acid sequence of the fusion protein of the heavy chain of humanized anti-hTfR antibody No. 3 and hα-GalA SEQ ID NO: 30: Primer Hyg-Sfi5', synthetic sequence SEQ ID NO: 31: Primer Hyg-BstX3', synthetic sequence SEQ ID NO: 32: Nucleotide sequence of GAA knockout vector, synthetic sequence
Claims
1. A pharmaceutical composition for improving dysfunction of skeletal muscle cells and cardiac muscle cells associated with Pompe disease, comprising a conjugate of an anti-human transferrin receptor antibody and human acid α-glucosidase, the amino acid sequence of the light chain variable region of the antibody is that shown in SEQ ID NO:22, or that in which 1 to 5 amino acids constituting the amino acid sequence shown in SEQ ID NO:22 have been substituted with other amino acids, and the light chain variable region comprises the amino acid sequence of SEQ ID NO:11 or 12 as CDR1, the amino acid sequence of SEQ ID NO:13 or 14 as CDR2, and the amino acid sequence of SEQ ID NO:15 as CDR3, The antibody has an amino acid sequence of a heavy chain variable region represented by SEQ ID NO:23, or an amino acid sequence represented by SEQ ID NO:23 in which 1 to 3 amino acids are substituted with other amino acids, and the heavy chain variable region comprises an amino acid sequence represented by SEQ ID NO:16 or 17 as CDR1, an amino acid sequence represented by SEQ ID NO:18 or 19 as CDR2, and an amino acid sequence represented by SEQ ID NO:20 or 21 as CDR3, The pharmaceutical composition is administered to a patient with Pompe disease by intravenous, subcutaneous, or intramuscular injection.
2. A pharmaceutical composition for improving dysfunction of skeletal muscle cells and cardiac muscle cells associated with Pompe disease, comprising a conjugate of an anti-human transferrin receptor antibody and human acid α-glucosidase, The light chain variable region contains the amino acid sequence shown in SEQ ID NO: 22, and the heavy chain variable region contains the amino acid sequence shown in SEQ ID NO:
23. The pharmaceutical composition is administered to a patient with Pompe disease by intravenous, subcutaneous, or intramuscular injection.
3. The pharmaceutical composition according to claim 1 or 2, which improves muscle weakness and hypotonia caused by skeletal muscle invasion.
4. 3. The pharmaceutical composition according to claim 1 or 2, which is supplied in the form of an aqueous solution.
5. The pharmaceutical composition of claim 4, wherein the concentration of the conjugate is 1 to 4 mg / mL.
Citation Information
Patent Citations
Anti-transferrin receptor antibody and method of use
JP2016526878A
Method for producing antibody fusion protein
JP2018033454A
Pharmaceutical agents fused with ATF for improved bioavailability
WO2013118165A1
Methods and compositions for treatment of pompe disease
WO2014130723A1
Anti-human transferrin receptor antibody permeating blood-brain barrier
WO2016208695A1
